[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 265
1. Schoene-Bake JC, Parpaley Y, Weber B, Panksepp J, Hurwitz TA, Coenen VA: Tractographic analysis of historical lesion surgery for depression. Neuropsychopharmacology; 2010 Dec;35(13):2553-63
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various surgical brain ablation procedures for the treatment of refractory depression were developed in the twentieth century.
  • It is possible that the observed clinical improvements of these various surgical procedures may reflect shared influences on presently unspecified brain affect-regulating networks.
  • Such possibilities can now be analyzed using modern brain connectivity procedures such as diffusion tensor imaging (DTI) tractography.
  • Accordingly, modestly sized historical lesions, especially of the anatomical overlap areas, were 'implanted' in brain-MRI scans of 53 healthy subjects.
  • [MeSH-major] Brain / anatomy & histology. Depression / surgery. Neural Pathways / anatomy & histology. Neuroanatomical Tract-Tracing Techniques / methods. Psychosurgery / methods

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • [Cites] Neurosurg Focus. 2008;25(1):E2 [18590379.001]
  • [Cites] Neurosurgery. 2002 May;50(5):1043-9; discussion 1049-52 [11950407.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Sep;42(9):365-71 [12371591.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3095-105 [12813115.001]
  • [Cites] Nat Neurosci. 2003 Jul;6(7):750-7 [12808459.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):199-212 [12856488.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):225-35 [12856490.001]
  • [Cites] Stereotact Funct Neurosurg. 2002;79(3-4):234-44 [12890982.001]
  • [Cites] Br J Psychiatry. 1969 Mar;115(520):257-66 [4893673.001]
  • [Cites] Exp Neurol. 1973 Sep;40(3):798-805 [4124980.001]
  • [Cites] Br J Psychiatry. 1973 Aug;123(573):141-8 [4582235.001]
  • [Cites] Med J Aust. 1973 Aug 25;2(8):366-71 [4749527.001]
  • [Cites] Postgrad Med J. 1973 Dec;49(578):860-4 [4618905.001]
  • [Cites] Br J Psychiatry. 1976 Mar;128:226-40 [1252686.001]
  • [Cites] Stereotact Funct Neurosurg. 1991;57(4):175-94 [1842976.001]
  • [Cites] J Clin Psychiatry. 1993 Nov;54(11):405-18 [8270583.001]
  • [Cites] Br J Psychiatry. 1994 Nov;165(5):599-611; discussion 612-3 [7866675.001]
  • [Cites] Annu Rev Psychol. 1995;46:209-35 [7872730.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Winter;7(1):103-12 [7711480.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):230-4 [7626968.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] Cereb Cortex. 2005 Jan;15(1):31-9 [15238447.001]
  • [Cites] Neuron. 2005 Mar 3;45(5):651-60 [15748841.001]
  • [Cites] Gesnerus. 2005;62(1-2):77-101 [16201322.001]
  • [Cites] Neuroimage. 2006 May 15;31(1):440-57 [16466680.001]
  • [Cites] Stereotact Funct Neurosurg. 2006;84(5-6):228-35 [17063044.001]
  • [Cites] Neuroimage. 2007 Jan 1;34(1):144-55 [17070705.001]
  • [Cites] Brain. 2007 Mar;130(Pt 3):630-53 [17293361.001]
  • [Cites] Neuroimage. 2007 May 1;35(4):1531-7 [17391987.001]
  • [Cites] Ann N Y Acad Sci. 2007 May;1104:70-88 [17344522.001]
  • [Cites] Brain Res Rev. 2007 Dec;56(2):283-321 [17905440.001]
  • [Cites] Neuropsychopharmacology. 2008 Jan;33(2):368-77 [17429407.001]
  • [Cites] J Clin Neurosci. 2008 Feb;15(2):138-42 [18068369.001]
  • [Cites] CNS Spectr. 2008 Aug;13(8):663-81 [18704022.001]
  • [Cites] Biol Psychiatry. 2008 Sep 15;64(6):461-7 [18639234.001]
  • [Cites] Psychiatry Res. 2008 Nov 30;164(2):132-42 [18945599.001]
  • [Cites] Nat Neurosci. 2009 Jan;12(1):32-4 [19029888.001]
  • [Cites] Biol Psychiatry. 2009 Feb 15;65(4):276-82 [19013554.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):717-25 [19339763.001]
  • [Cites] Science. 2009 Apr 17;324(5925):354-9 [19299587.001]
  • [Cites] Neurosurgery. 2009 Jun;64(6):1106-14; discussion 1114-5 [19487890.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1209-15 [19480538.001]
  • [Cites] Biol Psychiatry. 2010 Jan 15;67(2):117-24 [19819426.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):4-26 [19812543.001]
  • [Cites] CNS Drugs. 2010 Feb;24(2):131-61 [20088620.001]
  • [Cites] Neuron. 2010 Mar 25;65(6):748-51 [20346752.001]
  • [Cites] J Psychiatr Res. 2010 Aug;44(11):683-7 [20096858.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):570-82 [18255316.001]
  • [Cites] Biol Psychiatry. 2008 Apr 1;63(7):670-7 [17916331.001]
  • [Cites] Cereb Cortex. 2008 Jun;18(6):1374-83 [17928332.001]
  • [Cites] J Nerv Ment Dis. 2008 May;196(5):405-10 [18477883.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Aug 29;356(1412):1293-322 [11545704.001]
  • (PMID = 20736994.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3055575
  •  go-up   go-down


2. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
Genetic Alliance. consumer health - Brain Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


3. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


Advertisement
4. McCall T, Chin SS, Salzman KL, Fults DW: Tuberous sclerosis: a syndrome of incomplete tumor suppression. Neurosurg Focus; 2006;20(1):E3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis: a syndrome of incomplete tumor suppression.
  • The latter is a benign brain tumor of mixed neuronal and glial origin.
  • [MeSH-major] Hamartoma / complications. Tuberous Sclerosis / etiology. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / complications. Brain Neoplasms / genetics. Humans. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459993.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 92
  •  go-up   go-down


5. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


6. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM: Epidemiology of intracranial meningioma. Neurosurgery; 2005 Dec;57(6):1088-95; discussion 1088-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most frequently reported primary intracranial neoplasms, accounting for approximately 25% of all such lesions diagnosed in the United States.
  • Few studies have examined the risk factors associated with a diagnosis of meningioma with two categories of exposure, hormones (both endogenous and exogenous) and radiation, most strongly associated with meningioma risk.
  • Recent legislation passed in the United States (The Benign Brain Tumor Cancer Registries Amendment Act [H.R.
  • 5204]) mandates registration of benign brain tumors such as meningioma.
  • The increased emphasis on research dedicated to the study of brain tumors coupled with the advent of new tools in genetic and molecular epidemiology make the current era an ideal time to advance knowledge for intracranial meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331155.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA089017; United States / NCI NIH HHS / CA / 5R25-CA089017-03; United States / NCI NIH HHS / CA / P50-CA097257; United States / NCI NIH HHS / CA / R01-CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


7. Guan M, Chen Y: Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol; 2005 Nov;58(11):1175-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.
  • N-terminal truncated isoforms of p73 (DeltaNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice.
  • AIMS: To detect DeltaNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DeltaNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer.
  • RESULTS: A significant increase of DeltaNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples.
  • [MeSH-major] Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Prostatic Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1213-23 [11753569.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3369-73 [8324747.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):165-70 [11801554.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):636-41 [11830511.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):343-5 [11859417.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3598-602 [12097259.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4715-27 [12101410.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Acta Oncol. 2002;41(6):550-5 [12546528.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):174-81 [12806379.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):215-20 [12865464.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):162-6 [14618632.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1337-41 [15138575.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6905-11 [15501968.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2076-7 [9605745.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1154-8 [10393724.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):464-9 [11101847.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):883-7 [1350643.001]
  • [Cites] Chin Med J (Engl). 2000 Apr;113(4):299-302 [11775222.001]
  • (PMID = 16254107.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1770779
  •  go-up   go-down


8. Jensen TR, Schmainda KM: Computer-aided detection of brain tumor invasion using multiparametric MRI. J Magn Reson Imaging; 2009 Sep;30(3):481-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided detection of brain tumor invasion using multiparametric MRI.
  • PURPOSE: To determine the potential of using a computer-aided detection method to intelligently distinguish peritumoral edema alone from peritumor edema consisting of tumor using a combination of high-resolution morphological and physiological magnetic resonance imaging (MRI) techniques available on most clinical MRI scanners.
  • MATERIALS AND METHODS: This retrospective study consisted of patients with two types of primary brain tumors: meningiomas (n = 7) and glioblastomas (n = 11).
  • Meningiomas are typically benign and have a clear delineation of tumor and edema.
  • Four classifiers of differing designs were trained using morphological, diffusion-weighted, and perfusion-weighted features derived from MRI to discriminate tumor and edema, tested on edematous regions surrounding tumors, and assessed for their ability to detect nonenhancing tumor invasion.
  • Each classifier was able to identify areas of nonenhancing tumor invasion supported with adjunct images or follow-up studies.
  • CONCLUSION: The combination of features derived from morphological and physiological imaging techniques contains the information necessary for computer-aided detection of tumor invasion and allows for the identification of tumor invasion not previously visualized on morphological, diffusion-weighted, and perfusion-weighted images and maps.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711398.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA028500; United States / NCRR NIH HHS / RR / M01 RR000058; United States / NCI NIH HHS / CA / R21 CA109280; United States / NCI NIH HHS / CA / R01 CA082500; United States / NCRR NIH HHS / RR / M01-RR00058; United States / NCI NIH HHS / CA / R21 CA10928; United States / NCI NIH HHS / CA / R01 CA082500-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS185656; NLM/ PMC4321878
  •  go-up   go-down


9. Nakasu S, Fukami T, Jito J, Nozaki K: Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol; 2009;26(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and regrowth of benign meningiomas.
  • However, even benign meningiomas sometimes show relatively rapid growth and may recur after total removal.
  • We investigated 135 benign meningiomas, of which 120 were totally removed (Simpson's grade I-III).
  • On the other hand, the histological features of sheet-like growth, prominent nucleoli, and necrosis did not correlate with recurrence, because they were relatively rare in grade I tumors.
  • The patients with recurrent or residual tumors did not always receive adjuvant treatment.
  • Including subtotally treated tumors, the retreatment rate was 9.8% at 10 years and 25.6% at 20 years.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856217.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Mahoney NR, Liu GT: Benign recurrent sixth (abducens) nerve palsies in children. Arch Dis Child; 2009 May;94(5):394-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign recurrent sixth (abducens) nerve palsies in children.
  • Sixth nerve palsy can occur as a result of elevated intracranial pressure, neoplasm or trauma.
  • Reports from tertiary centres indicate that between 5% and 16% of referred cases have no ascribed aetiology and are classified as benign.
  • Rarely, these benign palsies can recur.
  • A retrospective chart review of a cohort of 253 paediatric patients with sixth nerve palsies was analysed and uncovered 30 cases of benign sixth nerve palsy, nine of which recurred.
  • Our data and review of other studies on the subject imply that a new onset sixth nerve palsy presenting in children can be benign in approximately 13% of cases, so a thorough history and physical examination to evaluate for any other neurological symptoms or signs followed by MRI of the brain with and without contrast is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131423.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. De Wever W, Bruyeer E, Demaerel P, Wilms G, Coolen J, Verschakelen J: Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases? JBR-BTR; 2010 Mar-Apr;93(2):71-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases?
  • Brain CT has been recommended in staging of patients with lung cancer because of its usefulness in the detection of metastases.
  • Purpose of this study is to examine if a diagnostic brain CT (CT,) can be obviated when an integrated PET/CT (PET/CT) is available.
  • 87 consecutive patients underwent a diagnostic brain CT and a whole-body PET/CT within a period of 3 weeks to stage a known primary tumour.
  • CT examinations were evaluated by two experienced neuroradiologists on the detection of brain lesions (benign and malignant).
  • Considering the CT, as standard of reference, sensitivity, specificity, PPV, NPV and accuracy for the brain CT of PET/CT (CT2) and PET/CT were respectively 83%, 96%, 77%, 97%, 94% and 69%, 98%, 90%, 95%, 94%.
  • Considering the clinical diagnosis as standard of reference these figures were for CT1, CT2 and PET/CT respectively 80%, 100%, 100%, 96%, 96% and 66%, 95%, 77%, 93%, 90% and 66%, 97%, 83%, 93%, 91%.
  • The comparison of the additional CT in PET/CT with a diagnostic CT of the brain did not yield a statistical difference in the detection of brain lesions despite the inferior quality of the CT component of PET/CT.
  • A diagnostic brain CT can be obviated when a PET/CT is available.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Brain / radiography. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Staging. Observer Variation. Radiographic Image Enhancement / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524514.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


12. Saraswathy A, Jayasree RS, Baiju KV, Gupta AK, Pillai VP: Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy. Photomed Laser Surg; 2009 Jun;27(3):425-33
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy.
  • OBJECTIVE: The role of autofluorescence spectroscopy in the detection and staging of benign and malignant brain tumors is being investigated in this study, with an additional aim of determining an optimum excitation wavelength for the spectroscopic identification of brain tumors.
  • MATERIALS AND METHODS: The present study involves in-vitro autofluorescence monitoring of different human brain tumor samples to assess their spectroscopic properties.
  • The autofluorescence measurement at four different excitation wavelengths 320, 370, 410, and 470 nm, were carried out for five different brain tumor types: glioma, astrocytoma, meningioma, pituitary adenoma, and schwannoma.
  • RESULTS: The fluorescence spectra of tumor tissues showed significant differences, both in intensity and in spectral profile, from those of adjacent normal brain tissues at all four excitation wavelengths.
  • Of the four excitation wavelengths being considered, 470 nm appeared to be the optimal wavelength for detecting tissue fluorescence of brain tumor tissues.
  • CONCLUSIONS: In conclusion, the spectroscopic luminescence measurements carried out in this study revealed significant differences between tumor tissue and adjacent normal tissue of human brains for all the tumor types tested, except for pituitary adenoma.
  • From the results of this study we conclude that excitation wavelengths ranging from 410-470 nm are most suitable for the detection of brain tumor tissue.
  • [MeSH-major] Brain Neoplasms / pathology. Spectrometry, Fluorescence / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Astrocytoma / pathology. Child. Child, Preschool. Discriminant Analysis. Female. Glioma / pathology. Humans. Male. Meningioma / pathology. Middle Aged. Neoplasm Staging. Neurilemmoma / pathology. Pituitary Neoplasms / pathology. Principal Component Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025404.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Monaco E 3rd, Kondziolka D, Mongia S, Niranjan A, Flickinger JC, Lunsford LD: Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery. Cancer; 2008 Nov 1;113(9):2610-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery.
  • BACKGROUND: Metastases to the brain from ovarian and endometrial carcinoma are uncommon and to the authors' knowledge consensus regarding optimal management is lacking.
  • Stereotactic radiosurgery (SRS) has proven useful for the treatment of many benign and malignant brain tumors.
  • METHODS: Twenty-seven patients with brain metastases underwent gamma-knife SRS.
  • Eighteen patients also received whole-brain radiotherapy.
  • A total of 68 tumors were treated with gamma-knife SRS.
  • The median survival was 7 months after the initial diagnosis of brain metastasis and 5 months after SRS.
  • The 1-year survival rate after radiosurgery was 15% and that from the diagnosis of brain metastases was 22%.
  • On final imaging, all tumors were controlled without further growth.
  • CONCLUSIONS: SRS is an acceptable choice for the treatment of brain metastases resulting from ovarian and endometrial carcinoma, and provides local tumor control with limited morbidity.
  • [MeSH-major] Brain Neoplasms / surgery. Cranial Irradiation. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Radiosurgery
  • [MeSH-minor] Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780313.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Maillo A, Orfao A, Espinosa AB, Sayagués JM, Merino M, Sousa P, Lara M, Tabernero MD: Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol; 2007 Oct;9(4):438-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
  • Tumor recurrence is the major clinical complication in meningiomas, and its prediction in histologically benign/grade I tumors remains a challenge.
  • In this study, we analyzed the prognostic value of specific chromosomal abnormalities and the genetic heterogeneity of the tumor, together with other clinicobiological disease features, for predicting early relapses in histologically benign/grade I meningiomas.
  • A total of 149 consecutive histologically benign/grade I meningiomas in patients who underwent complete tumor resection were prospectively analyzed.
  • From the prognostic point of view, losses of chromosomes 9, 10, 14, and 18 and del(1p36) were associated with a shorter RFS at 2.5, 5, and 10 years.
  • Similarly, histologically benign/grade I meningiomas showing coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone displayed a higher frequency of early relapses.
  • In fact, coexistence of -14 and del(1p36) in the ancestral tumor cell clone, together with tumor size, represented the best combination of independent prognostic factors for the identification of those patients with a high risk of an early relapse.
  • Our results indicate that patients with large histologically benign/grade I meningiomas carrying monosomy 14 and del(1p36) in their ancestral tumor cell clone have a high probability of relapsing early after diagnostic surgery.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Jul;28(7):779-85 [9224744.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):19-24 [1688296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Sep;55(3A):431-7 [9629361.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Ann Genet. 1998;41(3):164-75 [9833072.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] In Vivo. 2006 Mar-Apr;20(2):271-5 [16634530.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Clin Neuropathol. 2000 Nov-Dec;19(6):259-67 [11128617.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):377-85 [11466693.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] BMC Cancer. 2003 Mar 4;3:6 [12614485.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):123-8 [14734222.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Histopathology. 1993 Oct;23(4):349-53 [8300070.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):53-8 [8042555.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):101-4 [8548731.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1417-23 [8622857.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] J Neurosurg Sci. 1996 Mar;40(1):17-23 [8913957.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):611-6 [9053860.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 1986 May;22(1):63-8 [3456829.001]
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] Neurochirurgie. 1986;32(2):129-34 [3724942.001]
  • [Cites] Cancer Genet Cytogenet. 1987 May;26(1):127-41 [3470128.001]
  • [Cites] Clin Neuropathol. 1989 Jan-Feb;8(1):41-4 [2706843.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):104-7 [2589115.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Med Assoc Thai. 1997 Jul;80(7):473-8 [9277078.001]
  • (PMID = 17704362.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994101
  •  go-up   go-down


15. Kuo YH, Edgar MA, Luther N, Schwartz TH: Novel low-grade glioneuronal neoplasm presenting in an octogenarian: case report and review of the literature. Clin Neurol Neurosurg; 2006 Jun;108(4):426-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel low-grade glioneuronal neoplasm presenting in an octogenarian: case report and review of the literature.
  • Glioneuronal neoplasms are rare tumors that typically affect patients in the first three decades of life.
  • Since the publication of the World Health Organization (WHO) 2000 classification of tumors, further variants of these tumors have been reported.
  • MRI and CT scan revealed a ring-enhancing bihemispheric lesion in the premotor cortex consistent with a malignant primary brain tumor crossing the corpus collosum.
  • Histopathologic studies revealed a mixed glioneuronal tumor with benign characteristics.
  • A craniotomy was performed and the tumor was resected.
  • Glioneuronal tumors are extremely uncommon in the octogenarian population, however, it is important to include them in the differential diagnosis of intracerebral masses.
  • Radiographically, these lesions can mimic more aggressive primary brain tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neuroglia / pathology. Neurons / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758540.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 23
  •  go-up   go-down


16. McKinsey RD, Moritz CH, Meyerand ME, Tomé WA: Assessment of multiple task activation and reproducibility in patients with benign and low-grade neoplasm. Technol Cancer Res Treat; 2010 Aug;9(4):319-26
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of multiple task activation and reproducibility in patients with benign and low-grade neoplasm.
  • Twenty-four patients with proven benign and low-grade brain neoplasms each performed two iterations of four fMRI paradigms: language (word generation), primary and association auditory (text listening), upper limb fine motor control (alternating-limb bilateral finger tapping), and primary visual perception (reversing checkerboard).
  • [MeSH-major] Brain Mapping. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):329-38 [8869061.001]
  • [Cites] Comput Biomed Res. 1996 Jun;29(3):162-73 [8812068.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Sep;18(8):1529-39 [9296196.001]
  • [Cites] Magn Reson Imaging. 1998;16(2):105-13 [9508267.001]
  • [Cites] Neuroimage. 1998 Oct;8(3):249-61 [9758739.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1152-7 [16024896.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):938-44 [16611797.001]
  • [Cites] J Neurol. 2006 Apr;253(4):471-6 [16283098.001]
  • [Cites] J Magn Reson Imaging. 2006 Jun;23(6):808-15 [16649200.001]
  • [Cites] Head Face Med. 2006;2:20 [16817959.001]
  • [Cites] Neuropsychol Rev. 2007 Jun;17(2):145-55 [17484055.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):528-35 [18184849.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1563-72 [10947259.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9718-23 [10931954.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1030-7 [12063237.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):21-32 [12134916.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):652-7 [12695198.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(24):9868-72 [2124706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5951-5 [1631079.001]
  • [Cites] Radiology. 1994 Jan;190(1):85-92 [8259434.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Aug;18(7):1317-22 [9282862.001]
  • (PMID = 20626198.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109656; United States / NCI NIH HHS / CA / R01 CA109656-03; United States / NINDS NIH HHS / NS / 1F31NS5297-01; United States / NCI NIH HHS / CA / R01-CA109656
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS216845; NLM/ PMC2906819
  •  go-up   go-down


17. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - International Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19648771.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 57
  •  go-up   go-down


18. Huang CF, Chiou SY, Wu MF, Tu HT, Liu WS, Chuang JC: Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery. J Neurosurg; 2010 Dec;113 Suppl:97-104
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery.
  • The authors hypothesized that loss of tumor cells after Gamma Knife surgery (GKS) may alter the ADC value and used diffusion weighted MR imaging (DW imaging) to evaluate cellular changes in brain tumors to detect their treatment response and the efficacy of GKS.
  • METHODS: In this paper the authors describe a prospective trial involving 86 patients harboring 38 solid or predominantly solid brain metastases, 30 meningiomas, and 24 acoustic neuromas that were treated by GKS.
  • Follow-up MR images and clinical outcomes were reviewed at 3-month intervals for metastatic lesions and at 6-month intervals for benign tumors.
  • Calcification (p = 0.006) and tumor recurrence (p = 0.025) significantly prevented a rise in the ADC level.The mean ADC value for all solid acoustic neuromas was 1.06 ± 0.17 × 10-3 mm2/sec before GKS.
  • At the last mean MR imaging follow-up there appeared to be tumor enlargement in 3 patients (12.5%); however, since the ADC values in these patients were significantly higher than the preradiosurgery values, the finding was considered to be a sign of radiation necrosis rather than tumor recurrence.
  • The mean ADC value of metastatic tumors was 1.05 ± 0.12 × 10-3 mm2/sec before GKS.
  • Magnetic resonance imaging showed that 89% of these tumors had been controlled by GKS.
  • In some patients in whom imaging findings are equivocal, ADC values may also be used to distinguish radiation-induced necrosis from tumor recurrence.(DOI: 10.3171/2010.7.GKS10864)
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Diffusion Magnetic Resonance Imaging / methods. Image Processing, Computer-Assisted / methods. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Echo-Planar Imaging. Female. Humans. Male. Meningioma / pathology. Meningioma / surgery. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neuroma, Acoustic / pathology. Neuroma, Acoustic / surgery. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222290.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Juric-Sekhar G, Zarkovic K, Waeg G, Cipak A, Zarkovic N: Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain. Tumori; 2009 Nov-Dec;95(6):762-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain.
  • It results in the production of 4-hydroxynonenal (HNE), which plays a crucial role in hypoxic brain injury, neuronal degeneration and apoptosis.
  • The aim of this study was to evaluate the expression of HNE in 120 astrocytic and 40 ependymal tumors in relation to tumor type, grade of malignancy, angiogenesis, and presence of necrosis and apoptosis.
  • RESULTS: HNE-protein adducts were found in all tumors.
  • The incidence of HNE-immunopositive tumor cells increased with increasing grades of malignancy.
  • Significantly higher HNE expression was found in tumor cells of glioblastomas multiforme than in cells of pilocytic astrocytomas (P < 0.005), and in anaplastic ependymomas than in benign ependymomas (P < 0.01).
  • HNE-immunopositive tumor cells were distributed more diffusely than in perivascular locations (P < 0.05).
  • HNE was expressed in the endothelium of almost all tumor vessels, but its expression in the walls of the vessels was significantly higher in diffuse and anaplastic astrocytomas than in pilocytic astrocytomas and glioblastomas multiforme (P < 0.05).
  • The number of microvessels containing HNE in their endothelium and walls was significantly associated with the grade of malignancy in both astrocytic (P < 0.001) and ependymal tumors (P < 0.05), although microvessels in pilocytic astrocytomas were significantly more numerous (P < 0.05) than in diffuse astrocytomas.
  • CONCLUSIONS: LPO seems to be a common pathological process in astrocytic and ependymal glial tumors, proportional to the level of malignancy and neovascularization.
  • Therefore, HNE might be involved in the damage of brain cells and the induction of malignancy.
  • [MeSH-major] Aldehydes / analysis. Astrocytoma / chemistry. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Ependymoma / chemistry. Lipid Peroxidation. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210242.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Biomarkers, Tumor; 0 / Cross-Linking Reagents; 0 / Neoplasm Proteins; 29343-52-0 / 4-hydroxy-2-nonenal
  •  go-up   go-down


20. Nasseri K, Mills JR: Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005. Cancer Detect Prev; 2009;32(5-6):363-71
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005.
  • The purpose of this study was to compare the epidemiology of primary brain tumors in this ethnic population with the non-Hispanic, non-Middle Eastern White (NHNMW) in California.
  • Data for 683 cases of primary brain tumors (429 benign, 238 malignant, 16 uncertain) in the ME and 15,589 cases (8352 benign, 6812 malignant, 425 uncertain) in the NHNMW were available for this study.
  • RESULTS: ME patients were significantly (p < 0.05) younger and their age-adjusted incidence rates per 100,000 for benign tumors of 10.0 in men and 17.6 in women were higher than similar rates of 7.3 and 10.6 in the NHNMW group (p < 0.05).
  • Rates for malignant tumors were similar.
  • Also increased were benign tumors of the pituitary and pineal glands.
  • The overall mortality in patients with benign tumors was significantly lower than malignant tumors.
  • CONCLUSIONS: This study presents a significantly high incidence of benign meningioma in the ME population in California.
  • This may be due to higher susceptibility or exposure of this ethnic group to the risk factor(s) for this neoplasm.
  • Considering the reported causal association of benign meningioma with childhood radiation exposure from Israel, exposure to this risk factor in this ethnic group needs to be evaluated in future studies.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Dec 15;104(12):2798-806 [16288487.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Calif Med. 1949 Mar;70(3):189-93 [18112454.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):405-11 [18159978.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):470-80 [18206397.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1183-91 [18543070.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):266-72 [10670551.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):667-9 [11442620.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):205-11 [11554389.001]
  • [Cites] Neoplasma. 2001;48(6):442-4 [11949834.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer Detect Prev. 2003;27(3):203-8 [12787727.001]
  • [Cites] Br J Surg. 1977 Jul;64(7):457-9 [922301.001]
  • [Cites] Neuroepidemiology. 1989;8(6):283-95 [2586698.001]
  • [Cites] Health Inf Manag. 1997 Mar-May;27(1):31-8 [10169442.001]
  • [Cites] Cancer Detect Prev. 2007;31(5):424-9 [18023539.001]
  • (PMID = 19588542.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103457-02; United States / NCI NIH HHS / CA / CA103457; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCCDPHP CDC HHS / DP / U58 DP000807; United States / NCI NIH HHS / CA / N01PC54404; United States / NCI NIH HHS / CA / R03 CA103457-02; United States / NCI NIH HHS / CA / R03 CA103457; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-54404; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS140088; NLM/ PMC2785228
  •  go-up   go-down


21. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ: Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol; 2008 Nov;70(5):471-7; discussion 477
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence.
  • METHODS: Sixty-one patients with benign meningiomas were chosen for surgical treatment by the Group of Brain Tumors and Metastasis of the Department of Neurosurgery.
  • Tumors located in the cavernous sinus, tuberculum sellae, foramen magnum, ventricles, and petroclival region were excluded.
  • CONCLUSION: Peritumoral brain edema may be related to the invading potential of meningiomas and may play a role in the recurrence potential of the tumor.
  • [MeSH-major] Brain Edema / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Recurrence, Local / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586307.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


23. Wu C, Yen YS, Ho DM, Guo W: Primary neurocytoma in the spinal cord. A case report. Neuroradiol J; 2006 Nov 30;19(5):672-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytoma is defined as an intraventricular benign brain tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24351271.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M: Tumor recurrence and malignant progression of gangliogliomas. Cancer; 2008 Dec 15;113(12):3355-63
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor recurrence and malignant progression of gangliogliomas.
  • BACKGROUND: Most gangliogliomas (GGs) are benign tumors, but tumor recurrence and malignant progression are observed in some patients.
  • METHODS: The authors analyzed their experience with 4 recurrent/progressive GGs (World Health Organization [WHO] grade I), 21 tumors with atypical features (WHO grade II), and 5 tumors with anaplastic histologic features (WHO grade III).
  • RESULTS: The 5-year survival rates were only 79% for patients who had tumors with atypical features and 53% for patients who had WHO grade III tumors.
  • Secondary glioblastomas were diagnosed in 5 of 11 patients (45%) who underwent surgery for tumor recurrence.
  • Patients who had extratemporal tumors had a significantly shorter PFS (P = .01) but not OS.
  • Neuropathologic examination revealed the presence of a gemistocytic cell component (PFS, P = .025), a lack of protein droplets (OS, P = .04; PFS, P = .05), and focal tumor cell-associated CD34 immunolabeling (OS, P = .03) as significant predictors of an adverse clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Epilepsy / epidemiology. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988291.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Simon SL, Moonis G, Judkins AR, Scobie J, Burnett MG, Riina HA, Judy KD: Intracranial capillary hemangioma: case report and review of the literature. Surg Neurol; 2005 Aug;64(2):154-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Capillary hemangiomas are benign vascular lesions that commonly present at birth or in early infancy on the face, scalp, back, or chest.
  • The patient underwent a resection of her tumor, which was diagnosed as a capillary hemangioma by histopathologic examination.
  • The patient required 2 further resections after the lesion exhibited a rapid regrowth from residual tumor in the left transverse sinus.
  • [MeSH-major] Brain Neoplasms / surgery. Hemangioma, Capillary / surgery. Neoplasm Recurrence, Local / surgery. Pregnancy Complications, Neoplastic / surgery

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051010.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hu H, Yao HT, Zhang WP, Zhang L, Ding W, Zhang SH, Chen Z, Wei EQ: Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B; 2005 Jan;6(1):33-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors.
  • OBJECTIVE: To characterize the expression of aquaporin-4 (AQP4), one of the aquaporins (AQPs), in human brain specimens from patients with traumatic brain injury or brain tumors.
  • METHODS: Nineteen human brain specimens were obtained from the patients with traumatic brain injury, brain tumors, benign meningioma or early stage hemorrhagic stroke.
  • MRI or CT imaging was used to assess brain edema.
  • CONCLUSION: AQP4 expression increases in human brains after traumatic brain injury, within brain-derived tumors, and around brain tumors.
  • [MeSH-major] Aquaporins / metabolism. Brain Edema / metabolism. Brain Edema / pathology. Brain Injuries / metabolism. Brain Injuries / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):159-63 [10655103.001]
  • [Cites] Brain Res Mol Brain Res. 2000 May 31;78(1-2):131-7 [10891592.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):55-73 [12086708.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):565-9 [12650429.001]
  • [Cites] Acta Neuropathol. 2003 Aug;106(2):121-4 [12715185.001]
  • [Cites] J Biol Chem. 1988 Oct 25;263(30):15634-42 [3049610.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):171-80 [8987746.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16140-6 [9195910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6 [9751776.001]
  • (PMID = 15593389.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Aquaporins; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1390756
  •  go-up   go-down


27. Sundgren PC, Cao Y: Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am; 2009 Nov;19(4):657-68
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain irradiation: effects on normal brain parenchyma and radiation injury.
  • Radiation therapy is a major treatment modality for malignant and benign brain tumors.
  • Concerns of radiation effects on the brain tissue and neurocognitive function and quality of life increase as survival of patients treated for brain tumors improves.
  • In this article, the clinical and neurobehavioral symptoms and signs of radiation-induced brain injury, possible histopathology, and the potential of functional, metabolic, and molecular imaging as a biomarker for assessment and prediction of neurotoxicity after brain irradiation and imaging findings in radiation necrosis are discussed.
  • [MeSH-major] Brain / radiation effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Diagnostic Imaging / methods. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959011.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167505; NLM/ PMC5000393
  •  go-up   go-down


28. Saito R, Kumabe T, Watanabe M, Jokura H, Shibuya M, Nakazato Y, Tominaga T: Low-grade fibromyxoid sarcoma of intracranial origin. J Neurosurg; 2008 Apr;108(4):798-802
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The low-grade fibromyxoid sarcoma is a rare sarcoma of the deep soft tissue that is characterized as an indolent but metastasizing soft-tissue neoplasm with a deceptively benign histological appearance.
  • A high rate of local recurrence and eventual metastasis has been demonstrated for this tumor in deep soft tissue.
  • The tumor is still under control without any evidence of extracranial metastasis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / prevention & control. Radiosurgery. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377261.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Aoki T, Tashiro Y, Fujita K, Kajiwara M, Matsuda Y: [The evaluation of preoperative and postoperative frontal lobe functions in three operative cases of meningioma]. No Shinkei Geka; 2006 Feb;34(2):161-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three cases of frontal meningioma with their pre- and post-operative evaluations of higher brain functions, especially of frontal lobe functions.
  • All of the cases showed the improvement of the frontal lobe functions after the tumor removal.
  • The evaluations of frontal lobe functions in benign brain tumors such as a meningioma are reported only in a few cases.
  • The evaluations of frontal lobe functions in the operative cases of benign brain tumors provide many interesting and valuable informations about frontal lobe functions.
  • So we must be more interest in evaluations in higher brain functions and accumulate cases for the further analysis of higher brain functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485561.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer; 2009 Jul 21;101(2):303-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of tumour stem-like cells from benign tumours.
  • We set out to test whether tumour stem-like cells can be identified from benign tumours.
  • METHODS: Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas.
  • Characterisation of tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation, and stimulated hormone production assays.
  • The tumour-initiating capability of these tumour stem-like cells was tested in serial brain tumour transplantation experiments using SCID mice.
  • RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours.
  • Finally, we demonstrated that PASCs are pituitary tumour-initiating cells in serial transplantation animal experiments.
  • CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours.
  • The conclusions from this study may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-initiating cells in general.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):567-74 [15380249.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] Annu Rev Med. 1996;47:95-106 [8712806.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Endocrinol. 2005 Jan;184(1):41-50 [15642781.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):964-71 [15637144.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):456-66 [15795928.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Breast Cancer Res. 2008;10(2):105 [18423071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):541-50 [18462887.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Glia. 2006 Feb;53(3):294-303 [16265670.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72 [16562373.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2739-53 [17015435.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):139-53 [10657706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7 [10720059.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Clin Neurosurg. 2001;48:306-19 [11692649.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Pituitary. 2002;5(2):89-98 [12675506.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • (PMID = 19568241.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS048959-04; United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / NS048959; United States / NINDS NIH HHS / NS / R01 NS048959-04; United States / NINDS NIH HHS / NS / R56 NS048959; United States / NINDS NIH HHS / NS / R21 NS048879-02; United States / NINDS NIH HHS / NS / NS048879-02; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / NS048879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / Pituitary Hormones
  • [Other-IDs] NLM/ PMC2720199
  •  go-up   go-down


31. Palani M, Arunkumar R, Janardhanam VA: Biochemical and cytogenetic analysis of brain tissues in different grades of glioma patients. Ann Neurosci; 2010 Jul;17(3):120-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical and cytogenetic analysis of brain tissues in different grades of glioma patients.
  • BACKGROUND: Glioma, a neoplasm of neuroglial cells, is the most common type of brain tumor, constituting more than 50% of all brain tumors.
  • Ependymoma (n=10), Pilocytic astrocytoma (n=10) and patients with benign lesions (n=5) served as controls.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25205887.001).
  • [ISSN] 0972-7531
  • [Journal-full-title] Annals of neurosciences
  • [ISO-abbreviation] Ann Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4116979
  • [Keywords] NOTNLM ; Antioxidants / Biochemical profile in glioma / Chromosomal aberrations / Enzymes / Glioma
  •  go-up   go-down


32. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign meningioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm, Residual. Time Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919820.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


33. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Mar 1;67(5):1412-7 [1991305.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):976 [9255263.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):631-6 [9199633.001]
  • [Cites] Semin Diagn Pathol. 1995 May;12(2):193-206 [7638451.001]
  • [Cites] J Thorac Imaging. 2002 Jul;17 (3):227-9 [12082375.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(2):152-4 [2163798.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):207-14 [15043310.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):167-75 [2830799.001]
  • [Cites] J Laryngol Otol. 2004 Sep;118(9):724-6 [15509374.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3 [11242234.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Sep 3;129(36):1854-7 [15368156.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1823-4 [8651794.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):425-9 [10208464.001]
  • [Cites] Surg Neurol. 1988 May;29(5):410-3 [3363477.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


35. Fayed N, Modrego PJ: The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol; 2005 May;72(3):261-5
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours.
  • Conventional Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are the cornerstone in the initial evaluation of brain tumours.
  • The purpose of this study is to evaluate the contribution of Magnetic Resonance Spectroscopy (MRS) and Perfusion-weighted MRI to distinguish malignant from benign tumours.
  • We included 55 patients diagnosed with single brain tumour by CT and MRI, and final histopathological verification of the tumour type: 25 were low-grade gliomas, 8 anaplastic gliomas, 11 glioblastomas, and 11 solitary metastases.
  • We carried out brain MRS and dynamic perfusion-weighted echoplanar MRI in all cases.
  • In MRS, we found significant differences in Choline/Creatine ratios in relation to the tumour type with the highest values in high-grade gliomas and metastases.
  • We found no significant differences in the relative cerebral blood volume (rCBV) for every type of tumour.
  • The mean rCBV was 1.24 for benign tumours and 1.5 for the malignant ones(1.24 for low-grade gliomas, 1.91 for anaplastic gliomas, 1.03 for glioblastomas, and 1.57 for metastases).
  • We conclude that, individually considered, MRS is superior to Perfusion-weighted MRI in the initial assessment of brain tumours.
  • Perfusion MRI has not demonstrated predictive power to distinguish malignant from benign tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Echo-Planar Imaging. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / chemistry. Astrocytoma / diagnosis. Astrocytoma / pathology. Blood Volume / physiology. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Creatinine / metabolism. Female. Glioma / chemistry. Glioma / diagnosis. Glioma / pathology. Humans. Lactates / metabolism. Male. Middle Aged. Neoplasm Metastasis / diagnosis. ROC Curve. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] Acad Radiol. 2001 May;8(5):384-91 [11345268.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):783-9 [12185064.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Feb;21(2):357-66 [10696024.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Br J Neurosurg. 2002 Aug;16(4):329-34 [12389884.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1645-9 [11039343.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]
  • [Cites] Clin Radiol. 2004 Jan;59(1):77-85 [14697379.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):599-613 [12687914.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):823-9 [11564242.001]
  • [Cites] Invest Radiol. 1999 Mar;34(3):230-5 [10084669.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 15937650.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lactates; AYI8EX34EU / Creatinine; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


36. Settin A, Ali N, Salem FK: Cytokine gene polymorphisms in Egyptian cases with brain tumors. Egypt J Immunol; 2008;15(2):15-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in Egyptian cases with brain tumors.
  • Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • To evaluate the association of polymorphisms of cytokine genes with brain tumors in Egyptian patients.
  • This study included 45 cases affected by brain tumors.
  • Their median age was 45, diagnosed as 24 benign cases and 21 malignant cases, and their sex included 20 males and 25 females.
  • Cases affected with benign brain tumors, showed a significant higher frequency of IL-10(-1082) A/A genotype (OR = 8.04, P < 0.001), IL-6(-174) C/C genotype (OR = 6.3, P < 0.001) and TNF-alpha(-308) A/A (OR = 4.7, P < 0.05) with a significant lower frequency of IL-10(-1082) G/A genotype (OR = 0.1, P < 0.001), IL-6(-174) G/C (OR = 0.2, P = 0.001) and TNF-alpha(-308) G/A was found significantly low among the same groups (OR = 0.2, P < 0.001) compared to controls.
  • The frequency of cytokines genotype and allele in malignant brain cases and controls.
  • Comparing studied genotype frequencies among benign and malignant brain tumor cases no significant difference was found in the frequencies of all studied genotypes and alleles with a non significant trend for the benign cases to have higher frequency of IL-10(-1082) AA genotype.
  • In conclusion, cytokine gene polymorphisms have a certain pattern among brain tumor cases and can be considered a genetic marker of potential value in counseling and management.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306684.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


37. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soon thereafter, the patient began experiencing seizures, and on magnetic resonance imaging, he was found to have metastatic disease to the brain.
  • Patients who present with a thyroid nodule and who have a history of malignancy present a diagnostic dilemma: Is the nodule benign, a new primary, or a distant metastasis?
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


38. Takei H, Adesina AM, Powell SZ: Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. Neuropathology; 2009 Apr;29(2):181-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subependymal giant cell astrocytoma (SEGA) is a benign, slowly growing tumor typically occurring in the setting of tuberous sclerosis complex (TSC).
  • Postmortem examination of the brain revealed a single 2.1 x 1.0 x 0.8 cm intraventricular nodule in the lateral ventricle.
  • Histologically, it was composed of interlacing bundles of spindle-shaped tumor cells with thin delicate processes admixed with relatively large pleomorphic cells with abundant glassy eosinophilic cytoplasm, as seen in a SEGA.
  • Immunohistochemically, GFAP, S-100 protein, and neuron specific enolase were positive, and synaptophysin labeled a few tumor cells.
  • Also noted were rare isolated MM cells within the tumor (i.e., tumor-to-tumor metastasis).
  • The histopathological differential diagnosis was limited and included giant cell ependymoma and, much less likely, giant cell glioblastoma and pleomorphic xanthoastrocytoma.
  • Tumor metastasis to an occult SEGA is extremely rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Brain / pathology. Brain / physiopathology. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Melanoma / pathology. Melanoma / physiopathology. Melanoma / secondary. Neoplasm Metastasis. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673443.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


39. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • Thus, EMA was found to be of little value in the diagnosis of ependymoma and in the differentiation between different types and grades.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


40. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


41. Walker RA, Wadman MC: Headache in the elderly. Clin Geriatr Med; 2007 May;23(2):291-305, v-vi
MedlinePlus Health Information. consumer health - Headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Particular emphasis should be placed on excluding subarachnoid hemorrhage, subdural hematoma, giant cell arteritis, intracranial neoplasm, cerebrovascular accident, acute-angle-closure glaucoma, and infectious etiologies such as meningitis and encephalitis.
  • Once life-threatening disorders are excluded, the geriatrician can focus on more benign etiologies such as migraine, tension headache, and medication withdrawal.
  • This article discusses headaches that require emergent treatment and then describes more benign etiologies of headaches.
  • [MeSH-major] Brain Diseases / complications. Headache / etiology
  • [MeSH-minor] Aged. Carbon Monoxide Poisoning / complications. Carbon Monoxide Poisoning / diagnosis. Glaucoma, Angle-Closure / complications. Glaucoma, Angle-Closure / diagnosis. Headache Disorders, Primary / diagnosis. Humans. Meningitis / complications. Meningitis / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462518.001).
  • [ISSN] 0749-0690
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


42. Ferchichi L, Bellil S, Ben Hammouda K, Bellil K, Mekni A, Bettaieb I, Haouet S, Khaldi MM, Zitouna K, Kchir N: Anaplastic secretory meningioma: a case report. Pathologica; 2006 Apr;98(2):153-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretory meningiomas are rare histological subtypes of meningiomas with benign biological behaviour.
  • In this study, the authors describe the first case of secretory meningioma with many mitotic figures and brain invasion, and discuss the clinicopathologic features including immunohistochemical staining profile and ultrastructural appearance of this tumour.
  • A case of a 54-year-old man diagnosed with an intracranial tumour located in the left frontal lobe is presented.
  • On pre-contrast CT scans, the tumour was hypodense and the contrast enhancement was marked in the pseudo membrane.
  • The tumour was partially removed.
  • The histological diagnosis was secretory meningioma with many mitotic figures, a high MIB-1 labeling index and a brain invasion.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Carcinoembryonic Antigen / analysis. Combined Modality Therapy. Cranial Irradiation. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Mitotic Index. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929789.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


43. Gokce M: Analysis of isolated cranial nerve manifestations in patients with cancer. J Clin Neurosci; 2005 Nov;12(8):882-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prospective study over a 16 month period, 20 of 242 patients presented with isolated CN manifestations, and were assessed for the following: primary site; CN symptoms and signs; length of time between primary diagnosis and neurological involvement; and survival following the neurological diagnosis.
  • They included meningeal carcinomatosis (10/16), brain stem metastases (3/16), primary brain astrocytomas (1/16), and metastases out of the central nervous system (2/16).
  • Although most of the isolated CN manifestations were due to systemic metastasis, in particular to the meninges, up to 20% were related to benign conditions.
  • [MeSH-major] Cranial Nerve Diseases / etiology. Neoplasms / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / secondary. Middle Aged. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326269.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


44. Mattei TA, Mattei JA, Ramina R, Aguiar PH, Plese JP, Marino Jr R: Edema and malignancy in meningiomas. Clinics (Sao Paulo); 2005 Jun;60(3):201-6
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological classification was: benign meningioma--43 cases; atypical meningiomas--11 cases; malignant meningioma--1 case.
  • [MeSH-major] Brain Edema / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Severity of Illness Index. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962080.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


45. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Min ZG, Liu HJ, Li M, Liu LH, Jin CW, Zhang M: [Accuracy of MR perfusion weighted imaging for cerebral glioma grading: a meta-analysis]. Zhonghua Yi Xue Za Zhi; 2010 Nov 9;90(41):2927-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accuracy of MR perfusion weighted imaging for cerebral glioma grading: a meta-analysis].
  • CONCLUSION: the relative cerebral blood volume (rCBV) of MR PWI can be referred to differentiate malignant cerebral gliomas from benign ones with sound sensitivity and specificity.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211399.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


47. Keshavarzi S, Meltzer H, Ben-Haim S, Newman CB, Lawson JD, Levy ML, Murphy K: Initial clinical experience with frameless optically guided stereotactic radiosurgery/radiotherapy in pediatric patients. Childs Nerv Syst; 2009 Jul;25(7):837-44
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this study is to report our initial experience treating pediatric patients with central nervous system tumors using a frameless, optically guided linear accelerator.
  • RESULTS: Nine patients, ages ranging from 12 to 19 years old (median age 15 years old), with a variety of tumors have been treated.
  • CONCLUSION: Frameless stereotactic optically guided radiosurgery and radiotherapy provides a feasible and accurate tool to treat a number of benign and malignant tumors in children with minimal treatment-related morbidity.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Radiosurgery / methods. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Astrocytoma / pathology. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Medulloblastoma / radiotherapy. Medulloblastoma / surgery. Neoplasm Metastasis / radiotherapy. Pineal Gland / pathology. Pineal Gland / surgery. Pinealoma / radiotherapy. Pinealoma / surgery. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Prolactinoma / radiotherapy. Prolactinoma / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2001 May;17(6):341-6; discussion 347 [11417414.001]
  • [Cites] Pediatr Neurol. 1996 Oct;15(3):193-9 [8916155.001]
  • [Cites] Med Phys. 2002 Aug;29(8):1729-38 [12201420.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):585-97 [14628124.001]
  • [Cites] Neurosurgery. 2004 Jul;55(1):89-98; discussion 98-9 [15214977.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):916-24; discussion 924-5 [15458600.001]
  • [Cites] Br J Neurosurg. 1989;3(3):305-12 [2506900.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(4-5):219-21 [2135190.001]
  • [Cites] Neurosurg Clin N Am. 1992 Jan;3(1):167-90 [1633445.001]
  • [Cites] Acta Neurochir Suppl. 1994;62:83-7 [7717143.001]
  • [Cites] J Neurosurg Anesthesiol. 1995 Apr;7(2):100-8 [7772962.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2 [8692387.001]
  • [Cites] Pediatr Neurosurg. 1996;24(3):139-44 [8870017.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):193-201 [8873161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):875-82 [9240657.001]
  • [Cites] Anaesth Intensive Care. 1997 Dec;25(6):691-5 [9452856.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):573-80 [9806517.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):181-202 [10099088.001]
  • [Cites] Nature. 1958 Nov 1;182(4644):1222-3 [13590280.001]
  • [Cites] Childs Nerv Syst. 2005 Apr;21(4):301-7; discussion 308 [15654635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1467-72 [15817352.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):304-10 [15558704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):914-21 [16338096.001]
  • [Cites] NeuroRx. 2006 Apr;3(2):276-91 [16554265.001]
  • [Cites] Cancer Radiother. 2006 Sep;10(5):283-7 [16859948.001]
  • [Cites] Semin Oncol Nurs. 2006 Nov;22(4):221-32 [17095398.001]
  • [Cites] Med Dosim. 2007 Summer;32(2):121-33 [17472891.001]
  • [Cites] Cancer J. 2007 Mar-Apr;13(2):87-94 [17476136.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3 Suppl):130-40; discussion 140-1 [17876243.001]
  • [Cites] Clin Lung Cancer. 2007 Sep;8(8):488-92 [17922973.001]
  • [Cites] Med Phys. 2007 Oct;34(10):3962-70 [17985641.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1507-15 [18020920.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S69-77 [18076312.001]
  • [Cites] J Clin Anesth. 2007 Dec;19(8):616-8 [18083476.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E4 [18081481.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E5 [18081482.001]
  • [Cites] J Neurosurg Pediatr. 2008 Apr;1(4):296-304 [18377305.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S131-5 [18406912.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3):647-55; discussion 647-55 [18425011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1152-8 [11704340.001]
  • (PMID = 19326128.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2691523
  •  go-up   go-down


48. Gu TF, Xiao XL, Sun F, Yin JH, Zhao H: Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases. Chin Med Sci J; 2008 Sep;23(3):145-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases.
  • OBJECTIVE: To evaluate the values of whole body diffusion weighted imaging (DWI) in screening primary unknown tumor in patients with metastases.
  • METHODS: Totally, 34 patients with metastases of primary unknown tumors were scanned with whole body DWI, and conventional magnetic resonance (MR) imaging was performed if suspected lesions were detected.
  • All the metastases including 27 cases of osseous metastases, 2 brain metastases, 2 liver metastases, 1 pulmonary multiple metastasis, 1 neck metastasis and 1 malignant ascites, were diagnosed by computed tomography, single photon emission computed tomography, or MR imaging.
  • For the proven primary tumors diagnosed by biopsy or pathology of surgical specimens, apparent diffusion coefficient (ADC) values of the primary and metastatic lesions were measured respectively.
  • The sensitivity and specificity of this technique for screening primary tumors were evaluated.
  • RESULTS: We found 24 cases with suspected primary lesions, in which 23 lesions were proved to be primary tumors, and 1 was proved to be benign lesion.
  • And no definite primary lesion was found in 10 cases on whole body DWI, but in which 1 case was diagnosed with primary tumor by biopsy later, and the other 9 cases remained unknown within follow-up of over half a year.
  • The sensitivity and specificity of whole body DWI for searching primary tumors was 95.8% and 90.0%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853848.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Morokoff AP, Zauberman J, Black PM: Surgery for convexity meningiomas. Neurosurgery; 2008 Sep;63(3):427-33; discussion 433-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningiomas that occur over the convexity of the brain are the most common meningiomas, but little has been published about their contemporary management.
  • RESULTS: Convexity tumors represented 22% of all meningiomas operated on.
  • The pathology of the tumors was benign in 144 (88.3%), atypical in 16 (9.8%), and anaplastic/malignant in 3 (1.8%).
  • In six of the cases designated "benign," there were borderline atypical features.
  • The 5-year recurrence rate for benign meningiomas was 1.8%, atypical meningiomas 27.2%, and anaplastic meningiomas 50%.
  • The two cases of benign tumor recurrences involved tumors with borderline atypia and high MIB-1 indices.
  • The borderline atypical cases had a 5-year recurrence-free survival rate of only 55.9%, more closely approximating that of tumors designated "atypical."
  • Benign convexity meningiomas having a Simpson Grade I complete excision have a very low recurrence rate.
  • The recurrence rates of atypical and malignant tumors are significantly higher, and borderline atypical tumors should be considered to behave more like atypical rather than benign lesions.
  • Longer-term follow-up data are needed to more accurately determine the recurrence rates of benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Craniotomy / methods. Craniotomy / mortality. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812953.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


51. Wickremesekera A, Hovens CM, Kaye AH: Expression of ErbB-1 and 2 in vestibular schwannomas. J Clin Neurosci; 2007 Dec;14(12):1199-206
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These findings implicate a functional role of ErbB-2 in the benign nature of VS and that a rationale for using ErbB targeted therapies in VS may be warranted.
  • [MeSH-major] Cranial Nerve Neoplasms / metabolism. Neuroma, Acoustic / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis
  • [MeSH-minor] Animals. Blotting, Western. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cells, Cultured. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Immunoprecipitation. Mice. Neoplasm Proteins / chemistry. Neoplasm Proteins / isolation & purification

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964790.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


52. Bougrine F, Bacha D, Chouchane O, Laabidi B, Yeades M, Bouziani A: [Intracerebral schwannoma: case report]. Neurochirurgie; 2007 Nov;53(5):387-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was removed through a right parietal craniotomy.
  • The most popular hypothesis argues that these tumors arise from the proliferation of Schwann cells in the perivascular nerve plexii.
  • CONCLUSIONS: Intracerebral schwannoma is an extremely rare benign tumor.
  • The importance of recognizing this tumor is stressed, particularly in younger patients, given its benign nature, radiological resemblance to other tumors and favorable response to resection without toxic treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Neoplasm Metastasis. Neurosurgical Procedures. Seizures / etiology

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884108.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


53. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-four consecutive patients with suspected pulmonary neoplasms underwent tomographic (99m)Tc-octreotide scintigraphy and (18)F-FDG coincidence imaging using the same gantry.
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
  • Thirteen of the 44 patients had benign lung lesions.
  • In the 31 patients with malignant tumors, all 38 abnormal lymph nodes in 20 patients showed abnormal high focal uptake of (18)F-FDG; only 7 patients with 10 regional lymph adenopathies showed moderate uptake of (99m)Tc-octreotide.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • The final diagnosis was confirmed by histopathology or clinical follow-up.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


54. Galanov AV, Konovalov AN, Kornienko VN, Il'ialov SR, Kostiuchenko VV, Pronin IN, Mariashev SA, Iakovlev SB, Lubnin AIu, Serova NK, Nikonova NG: [First experience with a Gamma-knife unit used for radiosurgical treatment for intracranial space-occupying lesions]. Zh Vopr Neirokhir Im N N Burdenko; 2007 Jan-Mar;(1):3-10
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three hundred and six patients with various intracranial diseases (137 with malignant tumors, 136 with benign tumors, and 33 patients with vascular diseases) underwent radiosurgery on a Gamma-Knife unit for over 1.5 years, from May 2005 to October 2006.
  • [MeSH-major] Brain Diseases / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Child. Child, Preschool. Equipment Design. Eye Diseases / surgery. Female. Humans. Male. Meningioma / radiotherapy. Meningioma / surgery. Middle Aged. Neoplasm Metastasis. Neuroma, Acoustic / radiotherapy. Neuroma, Acoustic / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17526246.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


55. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res; 2007 Feb 1;67(3):930-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.
  • Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
  • Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1081-8 [12773490.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20812-20 [12676953.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):671-8 [15210852.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:2 [14711377.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33613-22 [15150279.001]
  • [Cites] J Cell Biol. 1984 Aug;99(2):753-7 [6378927.001]
  • [Cites] J Urol. 1988 Dec;140(6):1466-9 [3193516.001]
  • [Cites] J Urol. 1989 Jul;142(1):193-8 [2659823.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Prostate. 1991;18(3):201-14 [1902292.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1059-67 [1850957.001]
  • [Cites] Cancer Commun. 1991 Aug;3(8):255-64 [1653586.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3656-61 [8033079.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):114-23 [7604873.001]
  • [Cites] Am J Med Sci. 1996 Jul;312(1):8-11 [8686732.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):535-41 [10024688.001]
  • [Cites] APMIS. 1999 Jan;107(1):150-9 [10190292.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Prostate Cancer. 2004 Dec;3(3):150-6 [15636681.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2115-24 [15781621.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):533-49 [15948707.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5793-801 [16115918.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7635-43 [16140929.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4559-72 [16786000.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):71-9 [11115541.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):326-36 [11262189.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • (PMID = 17283123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NINDS NIH HHS / NS / NS 57529; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA 92393; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS14046; NLM/ PMC1832148
  •  go-up   go-down


56. Bertalanffy A, Roessler K, Koperek O, Gelpi E, Prayer D, Knosp E: Recurrent central neurocytomas. Cancer; 2005 Jul 1;104(1):135-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Since the first description of Central neurocytomas (CNs) as a benign tumor entity in 1982, there has been great enthusiasm regarding the benign course and the curative surgical approach to this disease.
  • The MIB-1 proliferation index ranged from 0.8-11% (median of 4.6%), but was reported to be 46.8% in the malignant transformed tumor.
  • [MeSH-major] Brain Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neurocytoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Kärjä V, Alafuzoff I: Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy. Clin Neuropathol; 2006 Jan-Feb;25(1):37-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy.
  • Expression of p62 has been seen in inclusions in neoplasias like hepatocellular and breast carcinomas but also in neuronal inclusions of degenerative brain disorders.
  • MATERIAL: The study material included 45 benign meningiomas of postmenopausal women operated in Kuopio University Hospital between 1994 and 2002.
  • CONCLUSION: Our results indicate that in the benign not recurrent meningiomas, signs of functioning proteosomal system, can be detected using the p62 labeling.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Biomarkers, Tumor / analysis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Brain / metabolism. Brain / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Postmenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465773.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / SQSTM1 protein, human
  •  go-up   go-down


58. Kreil W, Luggin J, Fuchs I, Weigl V, Eustacchio S, Papaefthymiou G: Long term experience of gamma knife radiosurgery for benign skull base meningiomas. J Neurol Neurosurg Psychiatry; 2005 Oct;76(10):1425-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term experience of gamma knife radiosurgery for benign skull base meningiomas.
  • OBJECTIVES: As most reports on the gamma knife have related only to short or mid-term results, we decided to evaluate the effectiveness and toxicity of radiosurgical treatment for benign skull base meningiomas in 200 patients with a follow up of 5-12 years to define the role of gamma knife radiosurgery (GKRS) for basal meningiomas and to provide further data for comparison with other treatment options.
  • Tumour volumes ranged from 0.38 to 89.8 cm3 (median 6.5 cm3), and doses of 7-25 Gy (median 12 Gy) were given to the tumour borders at covering isodose volume curves (range 20-80%, median 45%).
  • Worsening was transient in seven patients (3.5%) and unrelated to tumour or treatment in one (0.5%).
  • Because of the excellent long term tumour control rate and low morbidity associated with GKRS, this treatment option should be used more frequently in the therapeutic management of benign skull base meningiomas.
  • [MeSH-major] Meningioma / surgery. Radiosurgery / instrumentation. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Microsurgery / instrumentation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Postoperative Complications / epidemiology. Salvage Therapy / methods. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Aug;81(2):245-51 [8027808.001]
  • [Cites] Acta Neurochir (Wien). 1992;118(1-2):27-32 [1414527.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Acta Neurochir Suppl. 2002;84:71-6 [12379007.001]
  • [Cites] Br J Neurosurg. 1996 Feb;10(1):59-68 [8672260.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:129-33 [9032853.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):271-80 [10099092.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] Surg Neurol. 1999 Mar;51(3):268-73 [10086490.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):915-9; discussion 919-20 [8905745.001]
  • [Cites] Surg Neurol. 1999 Apr;51(4):412-9; discussion 419-20 [10199295.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):20-8 [8613831.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:112-20 [9032851.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] J Neurosurg. 2000 Jan;92(1 Suppl):71-80 [10616061.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:33-40 [9782233.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] Neurosurgery. 1993 May;32(5):699-704; discussion 704-5 [8492844.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;73(1-4):72-8 [10853105.001]
  • [Cites] Surg Neurol. 1997 Apr;47(4):371-9 [9122842.001]
  • [Cites] Surg Neurol. 1999 Jul;52(1):40-4; discussion 44-5 [10390171.001]
  • [Cites] Neurosurgery. 1996 Dec;39(6):1086-94; discussion 1094-5 [8938761.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Acta Neurochir (Wien). 2001 Nov;143(11):1141-52 [11731865.001]
  • [Cites] Neurosurgery. 1999 Jun;44(6):1194-9; discussion 1199-200 [10371618.001]
  • [Cites] Surg Neurol. 1996 Sep;46(3):272-8; discussion 278-9 [8781598.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1019-25; discussion 1025-7 [9361055.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):767-74; discussion 774-5 [9316037.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):437-43; discussion 443-5 [9526975.001]
  • [Cites] J Neurosurg. 1994 Dec;81(6):860-8 [7965116.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;72 Suppl 1:67-72 [10681693.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:107-12 [11143226.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):1-9; discussion 9-10 [8587667.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:12-4 [11386818.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):755-61 [2108937.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):813-28; discussion 828 [1436406.001]
  • [Cites] Minim Invasive Neurosurg. 1997 Sep;40(3):87-90 [9359085.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):879-85 [2777680.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):473-80 [10392202.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:219-22 [11143252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] Surg Neurol. 2001 Jun;55(6):325-31 [11483185.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):1021-6 [2120162.001]
  • [Cites] Stereotact Funct Neurosurg. 1993;61 Suppl 1:23-9 [8115752.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:19-32 [9782232.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):552-9 [2002367.001]
  • (PMID = 16170090.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  • [Other-IDs] NLM/ PMC1739368
  •  go-up   go-down


59. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol; 2006 Aug;27(7):1432-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
  • BACKGROUND AND PURPOSE: [(11)C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy.
  • METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B).
  • Semiquantitative methionine uptake indices (UI) defined by the tumor (maximum)-to-background ratio was correlated with tumor grade and final outcome.
  • Although a weak linear correlation between MET uptake and grading was observed (R = 0.38, P = .028), analysis of variance showed no significant differences in MET UI between tumor grades for either group A or B.
  • Benign and grade I lesions showed significant difference in MET uptake in comparison with higher grade lesions (P = .006).
  • Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Brain / metabolism. Child. Child, Preschool. Disease Progression. Female. Forecasting. Humans. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908552.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


60. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, Mayer J, Ludwig N, Hildebrandt A, Keller A, Steudel WI, Lenhof HP, Meese E: Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A; 2005 Jul 5;102(27):9601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets.
  • There are numerous studies on the immune response against malignant human tumors.
  • This study was aimed to address the complexity and specificity of humoral immune response against a benign human tumor.
  • We assembled a panel of 62 meningioma-expressed antigens that show reactivity with serum antibodies of meningioma patients, including 41 previously uncharacterized antigens by screening of a fetal brain expression library.
  • We detected 17 antigens exclusively with patient sera, including 12 sera that were reactive against KIAA1344, 9 against natural killer tumor recognition (NKTR), and 7 against SRY (sex determining region Y)-box2 (SOX2).
  • Our results show a highly complex but specific humoral immune response against a benign tumor with a distinct serum reactivity pattern and a decline of complexity with malignancy.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antibody Formation / immunology. Antigens, Neoplasm / immunology. Meningioma / immunology
  • [MeSH-minor] Antibody Specificity. Brain / metabolism. DNA Primers. Discriminant Analysis. Gene Library. Humans. Meninges / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Serologic Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3560-8 [10589772.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):815-26 [10499920.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 11;283(3):634-40 [11341771.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 18;290(2):830-8 [11785977.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):239-47 [11803467.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):25-31 [11926408.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5956-63 [14634107.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):257-63 [14719100.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1420-7 [14691456.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):51-60 [15305375.001]
  • [Cites] Hum Genet. 1987 Dec;77(4):349-51 [2891603.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5863-7 [2393856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):542-6 [8421688.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):686-96 [8373407.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Mol Biol Cell. 1996 Jul;7(7):1015-24 [8862517.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17907-11 [9218414.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2031-41 [9356211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Hum Mol Genet. 1998 Nov;7(12):1859-72 [9811929.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 [10037800.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203 [10760287.001]
  • (PMID = 15983380.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / DNA Primers
  • [Other-IDs] NLM/ PMC1172238
  •  go-up   go-down


61. Nakasu S, Fukami T, Jito J, Matsuda M: Microscopic anatomy of the brain-meningioma interface. Brain Tumor Pathol; 2005;22(2):53-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic anatomy of the brain-meningioma interface.
  • We analyzed the relation between meningioma and the brain in 50 surgical cases.
  • The other 19 tumors showed partial disruption of the arachnoid membrane.
  • The degree of arachnoid disruption correlated with the tumor grade, perifocal edema, pial blood supply on angiography, and tumor size.
  • The existence of brain invasion correlated with the tumor grade and partially with tumor size.
  • In case of invasive tumor, GFAP-positive cells were found deep in the tumor, usually in contact with blood vessels.
  • The axons in gliotic brain often showed degenerative changes such as ballooning or varicose swelling.
  • In two benign meningiomas that looked like an invasive growth, Col4 staining was seen above the brain.
  • A pia mater-like structure covered the tumor surface in both cases.
  • We could not demonstrate a relation between the expression of matrix metalloproteinase (MMP)-2 or MMP-9 and arachnoid disruption or brain invasion.
  • [MeSH-major] Brain / ultrastructure. Meningeal Neoplasms / ultrastructure. Meningioma / ultrastructure
  • [MeSH-minor] Amyloid beta-Protein Precursor / analysis. Arachnoid / ultrastructure. Brain Edema / etiology. Collagen Type IV / analysis. Glial Fibrillary Acidic Protein / analysis. Humans. Immunoenzyme Techniques. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neurofilament Proteins / analysis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095106.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


62. Prabhu SS, Bruner JM: Large oculomotor schwannoma presenting as a parasellar mass: A case report and literature review. Surg Neurol Int; 2010;1:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The common site of tumor occurrence in this nerve is the segment within the interpeduncular cistern and the cavernous sinus.
  • The radiological features of the mass were more consistent with a medial sphenoid wing meningioma causing brain stem compression.
  • Complete resection of the tumor was achieved via a left pterional approach.
  • CONCLUSION: The management of these large benign tumors with brain stem compression includes surgical resection.
  • Intraoperative anatomical preservation of the third nerve was impossible given its course in the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1992 Sep;38(3):216-24 [1440207.001]
  • [Cites] Neurochirurgie. 1992;38(3):183-7 [1461338.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Feb;30(2):132-6 [1695335.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(4):333-5 [1963824.001]
  • [Cites] Br J Neurosurg. 1990;4(1):69-72 [2185790.001]
  • [Cites] Surg Neurol. 1985 Sep;24(3):275-8 [4023908.001]
  • [Cites] Surg Neurol. 2007 Jan;67(1):83-8; discussion 88 [17210311.001]
  • [Cites] J Neurosurg. 1982 Jun;56(6):854-6 [7077388.001]
  • [Cites] J Neurosurg. 1982 Oct;57(4):563-5 [7108608.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(11):1147-51 [9870060.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):168-73 [12820761.001]
  • [Cites] Skull Base Surg. 1994;4(4):219-26 [17171175.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 May;44(5):397-401 [7021770.001]
  • (PMID = 20657696.001).
  • [ISSN] 2152-7806
  • [Journal-full-title] Surgical neurology international
  • [ISO-abbreviation] Surg Neurol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2908360
  • [Keywords] NOTNLM ; Meningioma / oculomotor schwannoma / skull base
  •  go-up   go-down


63. Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, Perry A: Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol; 2009 Sep;94(2):283-92
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature.
  • Dysembryoplastic neuroepithelial tumors (DNETs) have traditionally been viewed as benign "quasihamartomatous" tumors widely considered curable with surgery alone.
  • Although the radiology was often alarming (e.g., new ring enhancing mass), the pathology remained benign in most cases.
  • These findings suggest that these patients may need closer follow-up than initially suggested, lending further support to the notion that this tumor behaves more like a benign neoplasm, rather than a dysplastic or hamartomatous lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Neuroepithelial / pathology

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 1993 Apr;47(4):255-8 [8495572.001]
  • [Cites] Clin Neuropathol. 2004 Sep-Oct;23(5):223-31 [15581025.001]
  • [Cites] Brain. 1994 Jun;117 ( Pt 3):461-75 [8032857.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):267-80 [10359147.001]
  • [Cites] Neurosurgery. 1988 Nov;23(5):545-56 [3143922.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):333-6 [2403835.001]
  • [Cites] Pediatr Radiol. 2003 Mar;33(3):207-10 [12612823.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 May;62(5):530-7 [12769192.001]
  • [Cites] Pediatr Neurosurg. 2008;44(2):153-8 [18230932.001]
  • [Cites] Brain Tumor Pathol. 1999;16(2):81-5 [10746965.001]
  • [Cites] Brain Pathol. 2009 Jan;19(1):81-90 [18452568.001]
  • [Cites] Ann Diagn Pathol. 2003 Aug;7(4):240-4 [12913847.001]
  • [Cites] Neurology. 2004 Jun 22;62(12):2270-6 [15210893.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2799-808 [17973253.001]
  • [Cites] Pediatr Neurosurg. 1997 Jul;27(1):1-11 [9486830.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):829-34 [12748079.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):450-8 [11254766.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:a1-9 [12456321.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6 Suppl):509-12 [17566412.001]
  • [Cites] Acta Neuropathol. 1993;86(5):466-72 [8310797.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):333-6 [18552517.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):722-5 [10761668.001]
  • [Cites] Am J Clin Pathol. 1992 Mar;97(3):398-401 [1543164.001]
  • [Cites] J Neurooncol. 2006 May;78(1):59-62 [16314940.001]
  • (PMID = 19267228.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


64. Kousar A, Hosein MM, Ahmed Z, Minhas K: Rapid sarcomatous transformation of an ameloblastic fibroma of the mandible: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep;108(3):e80-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic fibrosarcoma (AFS) is a rare malignant odontogenic tumour regarded as the malignant counterpart of ameloblastic fibroma.
  • It is characterized by a benign epithelial component within a malignant fibrous stroma.
  • AFS is a locally aggressive neoplasm with extremely low potential for metastasis.
  • Initially histopathologically diagnosed as a benign lesion, it rapidly recurred with apparent transformation into a high-grade sarcoma over a period of 6 months.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Odontogenic Tumors / pathology. Sarcoma / pathology
  • [MeSH-minor] Brain Neoplasms / secondary. Fatal Outcome. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Masseter Muscle / pathology. Muscle Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Radiography, Panoramic. Skull Neoplasms / pathology. Sphenoid Bone / pathology. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716496.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


65. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT: Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res; 2009 Aug;29(8):3269-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To evaluate the expression of CD68 and kallikrein 6 in human gliomas, and investigate their prognostic significance for survival of brain cancer patients in comparison to some known prognostic markers.
  • PATIENTS AND METHODS: Histological sections of 51 primary astrocytic tumours (11 benign, 40 malignant) were immunohistochemically stained for CD68, cathepsin B, kallikrein 6 and Ki-67.
  • CD68 and kallikrein 6 expressions were also analyzed by real-time PCR in nine brain tumour biopsies.
  • RESULTS: Both microglia and tumour cells expressed CD68.
  • High CD68 and cathepsin B staining scores were significantly, more frequent in the malignant than in the benign tumours (p=0.036 and p=0.014, respectively).
  • In contrast, the benign group presented a stronger immunoreactivity for kallikrein 6 compared with the malignant tumours (p=0.013).
  • A CD68 staining score of tumour cells higher than 3 was a significant predictor of shorter overall survival (p<0.01) in all patients and of borderline significance in the malignant group (p=0.057).
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Kallikreins / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661345.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / RNA, Messenger; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


66. Sasikala M, Kumaravel N: A wavelet-based optimal texture feature set for classification of brain tumours. J Med Eng Technol; 2008 May-Jun;32(3):198-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A wavelet-based optimal texture feature set for classification of brain tumours.
  • In this work, the classification of brain tumours in magnetic resonance images is studied by using optimal texture features.
  • These features are used to classify three sets of brain images - normal brain, benign tumour and malignant tumour.
  • Each selected brain region of interest is characterized with both its energy and texture features extracted from the selected high frequency subband.
  • [MeSH-major] Algorithms. Artificial Intelligence. Brain Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432467.001).
  • [ISSN] 0309-1902
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Mnif I, Chaker M, Daoud E, Ben Mahfoudh K, Mnif Z, Mnif J: [Central neurocytoma: three case reports]. J Neuroradiol; 2008 Mar;35(1):56-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neurocytome central: à propos de trois observations.
  • Central neurocytoma is classically recognized as an intraventricular benign brain tumour.
  • Histologically, central neurocytoma presents remarkable likeness characteristics to oligodendroglioma, but immunohistochemical study distinguishes this tumour.
  • Imaging appearances (CT, MRI) raise the diagnosis and immunohistochemical study confirm it.
  • The purpose of our work is to assess the value of imaging (CT, MRI) in the diagnosis of central neurocytoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617462.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


68. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


69. Schaller BJ, Modo M, Buchfelder M: Molecular imaging of brain tumors: a bridge between clinical and molecular medicine? Mol Imaging Biol; 2007 Mar-Apr;9(2):60-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?
  • As the research on cellular changes has shed invaluable light on the pathophysiology and biochemistry of brain tumors, clinical and experimental use of molecular imaging methods is expanding and allows quantitative assessment.
  • Molecular imaging sets forth to probe the molecular abnormalities that are the basis of disease rather than to visualize the end effects of these molecular alterations and, therefore, provides different additional biochemical or molecular information about primary brain tumors compared to histological methods "classical" neuroradiological diagnostic studies.
  • Common clinical indications for molecular imaging contain primary brain tumor diagnosis and identification of the metabolically most active brain tumor reactions (differentiation of viable tumor tissue from necrosis), prediction of treatment response by measurement of tumor perfusion, or ischemia.
  • The interesting key question remains not only whether the magnitude of biochemical alterations demonstrated by molecular imaging reveals prognostic value with respect to survival, but also whether it identifies early disease and differentiates benign from malignant lesions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurons / diagnostic imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Animals. Cell- and Tissue-Based Therapy. Disease Models, Animal. Disease Progression. Humans. Molecular Probes. Neoplasm Staging. Radiography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Jun;111(11):1620-9 [12782662.001]
  • [Cites] Nucl Med Commun. 2003 Nov;24(11):1149-54 [14569169.001]
  • [Cites] Acta Radiol. 1989 Mar-Apr;30(2):121-8 [2493795.001]
  • [Cites] J Nucl Med. 1993 Jan;34(1):12-7 [8418251.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] Expert Opin Biol Ther. 2004 Feb;4(2):145-55 [14998774.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Jun;38(6):342-7; discussion 347-8 [9689817.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):309-35 [12926228.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8122-5 [14678964.001]
  • [Cites] J Comput Assist Tomogr. 1993 Sep-Oct;17 (5):681-7 [8370819.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25 [15877226.001]
  • [Cites] Nucl Med Biol. 2004 Feb;31(2):179-89 [15013483.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):653-9 [15711980.001]
  • [Cites] Expert Rev Neurother. 2006 May;6(5):723-30 [16734520.001]
  • [Cites] Neuroradiology. 1998 Feb;40(2):103-8 [9541920.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1862-7 [11912166.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] J Neurooncol. 2004 May;68(1):1-9 [15174514.001]
  • [Cites] Acta Neurol Scand. 2005 Feb;111(2):75-83 [15644065.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):726-8 [2013813.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(2):103-11 [12132049.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):414-6 [15770001.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1530-8 [15378285.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1255-62 [14977823.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7571-4 [14633668.001]
  • [Cites] Hum Gene Ther. 2003 Feb 10;14(3):277-97 [12639307.001]
  • [Cites] Radiology. 2001 May;219(2):316-33 [11323453.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):491-5 [11228541.001]
  • [Cites] J Neurooncol. 1992 Feb;12 (2):159-65 [1560262.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Dev Neurosci. 2004 Mar-Aug;26(2-4):118-30 [15711055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51 [11070094.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(1):1-15 [10664370.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Acta Radiol Suppl. 1986;369:157-60 [2980438.001]
  • [Cites] J Neurochem. 1977 May;28(5):897-916 [864466.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):498-507 [16235683.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jan-Feb;16(1):62-8 [1729308.001]
  • [Cites] Chest. 2003 Aug;124(2):608-13 [12907550.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):994-1002; discussion 1002 [8084410.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19745-51 [10391916.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):727-9 [11551583.001]
  • [Cites] NeuroRx. 2005 Apr;2(2):333-47 [15897954.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74 [16111573.001]
  • [Cites] Radiology. 1995 Oct;197(1):221-6 [7568827.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Acta Otolaryngol. 1997 Jul;117(4):482-9 [9288200.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):509-61 [8392523.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] J Nucl Med. 2005 Mar;46(3):450-4 [15750158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] NMR Biomed. 2003 Apr;16(2):67-76 [12730947.001]
  • [Cites] Eur J Nucl Med. 2001 Dec;28(12 ):1851-72 [11734927.001]
  • [Cites] Invest Radiol. 1987 May;22(5):360-71 [3496318.001]
  • [Cites] Mol Imaging Biol. 2004 Jul-Aug;6(4):239-69 [15262239.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):207-15 [15332323.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] Mol Imaging Biol. 2004 May-Jun;6(3):139-48 [15193248.001]
  • [Cites] Eur J Nucl Med. 1997 Sep;24(9):1149-55 [9283109.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):893-9 [15122670.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):467-75 [11337525.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] J Nucl Med. 2000 Apr;41(4):661-81 [10768568.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6101-8 [15342393.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):789-803; discussion 803-4 [9092853.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12 ):1962-9 [14660722.001]
  • [Cites] Nat Biotechnol. 2003 Apr;21(4):405-13 [12652311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9300-5 [11481488.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]
  • [Cites] Q J Nucl Med. 1995 Sep;39(3):243-9 [7552947.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):1948-58 [16330557.001]
  • [Cites] J Neurosurg. 1999 Nov;91(5):797-803 [10541237.001]
  • [Cites] Eur J Nucl Med. 1997 Apr;24(4):428-34 [9096095.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:139-43 [12401680.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2572-9 [15059914.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11 [16145529.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):916-28 [15509509.001]
  • [Cites] Leukemia. 2002 Feb;16(2):260-7 [11840293.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51 [15014901.001]
  • [Cites] J Cereb Blood Flow Metab. 1984 Jun;4(2):212-23 [6609929.001]
  • [Cites] Blood. 2005 Jan 1;105(1):420-5 [15331444.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] J Nucl Med. 1994 Jul;35(7):1162-6 [8014676.001]
  • [Cites] Nat Med. 2000 Apr;6(4):447-50 [10742153.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):28-33 [8355844.001]
  • [Cites] J Cereb Blood Flow Metab. 1991 May;11(3):485-91 [2016357.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] J Magn Reson Imaging. 2004 Apr;19(4):389-96 [15065161.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):323-9 [15925587.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] J Nucl Med. 1999 Mar;40(3):381-6 [10086699.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):720-8 [2586726.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1257-60 [15502845.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5347-54 [15289341.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] J Nucl Med. 1991 Jul;32(7):1338-46 [1906093.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1369-74 [9293789.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2983-95 [11306477.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Trends Neurosci. 2005 Mar;28(3):120-6 [15749164.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):265-72 [11134222.001]
  • [Cites] Clin Nucl Med. 1996 Sep;21(9):720-5 [8879874.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Nervenarzt. 2003 Dec;74(12):1134-6 [14647916.001]
  • [Cites] Neurobiol Dis. 2004 Apr;15(3):437-48 [15056451.001]
  • [Cites] Radiographics. 1992 Mar;12 (2):269-79 [1561416.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] Eur J Nucl Med. 1996 May;23 (5):583-6 [8698067.001]
  • [Cites] Pediatr Neurosurg. 1997 Mar;26(3):144-56 [9419031.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1939-45 [15534066.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2836-42 [7954245.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1074-8 [3261622.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):816-22 [2987440.001]
  • (PMID = 17203238.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes
  • [Number-of-references] 135
  •  go-up   go-down


70. Fayed-Miguel N, Morales-Ramos H, Modrego-Pardo PJ: [Magnetic resonance imaging with spectroscopy, perfusion and cerebral diffusion in the diagnosis of brain tumours]. Rev Neurol; 2006 Jun 16-30;42(12):735-42
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Magnetic resonance imaging with spectroscopy, perfusion and cerebral diffusion in the diagnosis of brain tumours].
  • [Transliterated title] Resonancia magnética con espectroscopia, perfusión y difusión cerebral en el diagnóstico de los tumores cerebrales.
  • AIM: We review three of the most important functional techniques in magnetic resonance imaging, it means spectroscopy, perfusion and diffusion; we do emphasize in its applications, particularly in the diagnostic and treatment of brain tumors.
  • DEVELOPMENT AND CONCLUSIONS: Choline containing compounds using contralateral creatine and choline for normalization or ipsilateral N-acetyl-aspartate appeared to correlate best with the degree of tumor infiltration, regardless o tumor histological grade.
  • Magnetic resonance spectroscopy imaging (MRSI) seems more accurate than conventional magnetic resonance imaging (MRI) in defining indistinct tumor boundaries and quantifying the degree of tumor infiltration.
  • Angiogenesis, and increased vascular permeability, are characteristic of cerebral neoplasms; these processes can be imaged using perfusion MRI.
  • Most commonly, tumor perfusion is measured using rapid gradient T2-weighted imaging during bolus injection of gadolinium dimeglumine gadopentetate.
  • Care has to be taken to avoid blood-brain barrier leakage affecting perfusion results.
  • Pharmacokinetic models are available for estimation of blood-brain permeability.
  • Cerebral blood volume increases with tumor grade, and maybe helpful in identifying tumor recurrence, and peri-tumoral edema, and distinguishing malignant from benign lesions.
  • [MeSH-major] Brain Neoplasms. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Biomarkers, Tumor / chemistry. Biomarkers, Tumor / metabolism. Blood-Brain Barrier / physiology. Brain Chemistry. Cerebrovascular Circulation. Choline / chemistry. Choline / metabolism. Contrast Media / metabolism. Image Processing, Computer-Assisted. Neoplasm Staging. Permeability. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775800.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; N91BDP6H0X / Choline
  •  go-up   go-down


71. Abe T, Inoue R, Isono M, Ishii K, Fujiki M, Kamida T, Kobayashi H, Kashima K, Kusakabe T, Nakazato Y: Benign pleomorphic astrocytoma in the hypothalamus--case report. Neurol Med Chir (Tokyo); 2006 Feb;46(2):101-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleomorphic astrocytoma in the hypothalamus--case report.
  • A 41-year-old woman presented with an unusual case of benign astrocytoma with marked pleomorphism manifesting as consciousness disturbance due to intraventricular hemorrhage.
  • Despite partial resection of the tumor without additional therapy, there have been no signs of tumor regrowth for 6 years.
  • The histological findings revealed solid proliferation of tumor cells with marked pleomorphism, contrary to the benign clinical course.
  • Immunohistochemical staining indicated the glial origin of the tumor.
  • The tumor was similar to pleomorphic xanthoastrocytoma, but the histological findings were not exactly identical, indicating a new histological entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hypothalamus / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498222.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Jinhu Y, Jianping D, Jun M, Hui S, Yepeng F: Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature. J Neurooncol; 2007 May;83(1):47-52
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature.
  • Cerebrospinal metastases of benign choroid plexus papillomas (CPPs) are extremely rare.
  • Plain CT scan of the cranium revealed a partly calcified tumor filling the fourth ventricle and its right recess.
  • Cranial MRI showed an inhomogeneously contrast-enhancing tumor and leptomeningeal enhancement encasing the brain stem.
  • Complete resection of the tumor was carried out, and seedings to the floor of the fourth ventricle and cervico-medullary junction were found during the operation.
  • While intraoperative frozen section suggested pathology of papillary ependymoma or CPP, to our surprise, final histological examination revealed a benign choroid plexus papilloma.
  • Two months after the first operation, on follow-up MRI of the cranium, the leptomeningeal enhancement encasing the brain stem had resolved spontaneously.
  • This special case helps increase our understanding of benign CPPs and expands our differential diagnostic consideration of lesions with similar manifestations.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Cerebral Ventricle Neoplasms / secondary. Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / secondary. Fourth Ventricle. Papilloma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Seeding. Neurosurgical Procedures / adverse effects. Subarachnoid Space. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1970 Nov;110(3):608-17 [5489698.001]
  • [Cites] Surg Neurol. 1999 Jun;51(6):621-9 [10369230.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):956-63 [11035346.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Sep;100(3):165-86 [9822838.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jan;33(1):32-5 [7680781.001]
  • [Cites] Neurochirurgie. 1986;32(3):258-61 [3762840.001]
  • [Cites] Neurosurg Focus. 2006 Jan 15;20(1):E10 [16459990.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jul;101(7):366-8 [577391.001]
  • [Cites] Neuroradiology. 2000 Sep;42(9):657-61 [11071438.001]
  • [Cites] Pediatr Neurosci. 1985-1986;12(4-5):196-201 [3843618.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]
  • [Cites] Br J Radiol. 1992 Sep;65(777):754-7 [1393408.001]
  • [Cites] Neurology. 2005 Sep 27;65(6):842 [16186520.001]
  • [Cites] J Neurosurg. 1960 Nov;17:1002-27 [13768200.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):85-90 [8744814.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):564-5 [2058519.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 May-Jun;8(3):469-72 [3111207.001]
  • [Cites] Surg Neurol. 1982 Nov;18(5):367-71 [6983728.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):723-8 [12181706.001]
  • [Cites] Neurology. 1995 Oct;45(10):1801-7 [7477972.001]
  • [Cites] Neurosurg Rev. 1981;4(3):129-37 [7301142.001]
  • [Cites] Aust N Z J Med. 1997 Oct;27(5):597-8 [9404596.001]
  • [Cites] Folia Neuropathol. 2001;39(3):209-13 [11770132.001]
  • [Cites] Surg Neurol. 1987 May;27(5):466-8 [3563861.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):633-8 [8010262.001]
  • (PMID = 17387433.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


73. Campos WK, Linhares MN: Sporadic intramedullary spinal cord hemangioblastoma in a newborn. Pediatr Neurosurg; 2010;46(5):385-9
Genetic Alliance. consumer health - Hemangioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemangioblastomas (HB) are rare lesions accounting for 2% of all spinal cord tumors.
  • They are highly vascular, benign tumors that occur either sporadically or in the presence of von Hippel-Lindau disease.
  • MRI of the spine revealed an intramedullary tumor extending from level T6 to T12.
  • RESULTS: The tumor was excised completely, using standard microsurgical techniques via a posterior approach.
  • The histological diagnosis was spinal cord HB.
  • CONCLUSION: A review of the literature revealed that this neoplasm is composed of 3 major cell types: endothelial cells, pericytes and stromal cells.
  • Complete microsurgical removal is the treatment of choice for spinal cord HB because the tumor is benign.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389752.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


74. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • BACKGROUND: Tumor-to-tumor metastasis is a rare, but well-reported, curiosity in which one type of primary neoplasm metastasizes to another primary tumor type within the same person.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • The second patient carried a diagnosis of marginal zone lymphoma but then presented 5 years later with symptoms referable to a large dural-based mass with significant surrounding edema, prompting surgical removal.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • In examples where the donor tumor type is a hematopoietic neoplasm, significant edema can be produced by the tumor-to-tumor metastasis.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Brain / pathology. Brain / surgery. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Meninges / surgery. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Marshall AE, Martin SE, Agaram NP, Chen JH, Horn EM, Douglas-Akinwande AC, Hattab EM: A 61-year-old woman with osteomalacia and a thoracic spine lesion. Brain Pathol; 2010 Mar;20(2):499-502
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phosphaturic mesenchymal tumor, mixed connective tissue variant (PMT-MCT) is a rare, largely benign, mesenchymal neoplasm almost invariably associated with oncogenic osteomalacia.
  • [MeSH-major] Osteomalacia / diagnosis. Osteomalacia / pathology. Spinal Neoplasms / diagnosis. Spinal Neoplasms / pathology. Thoracic Vertebrae
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasms, Complex and Mixed / complications. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Complex and Mixed / pathology. Neoplasms, Connective Tissue / complications. Neoplasms, Connective Tissue / diagnosis. Neoplasms, Connective Tissue / pathology

  • Genetic Alliance. consumer health - Osteomalacia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438469.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


76. Santelli L, Ramondo G, Della Puppa A, Ermani M, Scienza R, d'Avella D, Manara R: Diffusion-weighted imaging does not predict histological grading in meningiomas. Acta Neurochir (Wien); 2010 Aug;152(8):1315-9; discussion 1319
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study aims to verify the reliability of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) measurements to differentiate benign from atypical/malignant meningiomas and among different sub-types.
  • DWI signal intensity of tumors was classified as hypo-, iso- or hyper-intense to grey matter.
  • RESULTS: Meningiomas were histologically graded as malignant (1%), atypical (21.5%) and benign (77.5%).
  • Meningothelial, transitional and fibrous were the most frequent benign sub-types (44, 16 and 10 cases, respectively).
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / pathology. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Middle Aged. Observer Variation. Predictive Value of Tests. Prognosis. Reproducibility of Results. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428902.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


77. Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY: Do serum biomarkers really measure breast cancer? BMC Cancer; 2009 May 28;9:164
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classifiers distinguished normal tissue from benign lesions similarly at AUC = 0.80 +/- 0.05.
  • However, the serum proteins of benign and malignant lesions were indistinguishable (AUC = 0.55 +/- 0.06).
  • The classification tasks of normal vs. cancer and normal vs. benign selected the same top feature: MIF, which suggests that the biomarkers indicated inflammatory response rather than cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biomark. 2006;2(6):235-48 [17264395.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41 [17301268.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2470-6 [17594124.001]
  • [Cites] Med Decis Making. 2000 Jul-Sep;20(3):323-31 [10929855.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1509-22 [10947254.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1):53-67 [11254867.001]
  • [Cites] Proteomics. 2001 Oct;1(10):1205-15 [11721633.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2391-4 [12089442.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1194-7 [12142372.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] Proteomics. 2003 Apr;3(4):433-9 [12687611.001]
  • [Cites] J Neurochem. 2003 Jul;86(2):519-28 [12871593.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Thyroid. 2003 Jun;13(6):547-51 [12930598.001]
  • [Cites] Radiology. 2003 Oct;229(1):3-8 [14519861.001]
  • [Cites] Med Phys. 2004 Jan;31(1):81-90 [14761024.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):559-63 [14726467.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1767-75 [15386335.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3221-4 [15510614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Dec;73(12):4329-33 [188033.001]
  • [Cites] Radiology. 1984 Feb;150(2):335-7 [6691085.001]
  • [Cites] Radiology. 1987 Jan;162(1 Pt 1):167-70 [3024209.001]
  • [Cites] Invest Radiol. 1988 Oct;23(10):729-33 [3056868.001]
  • [Cites] Blood. 1989 May 1;73(6):1504-12 [2653458.001]
  • [Cites] Breast Cancer Res Treat. 1989 Mar;13(2):123-33 [2730960.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):193-9 [2295042.001]
  • [Cites] Endocrinol Jpn. 1989 Dec;36(6):873-9 [2483831.001]
  • [Cites] Immunol Today. 1993 Oct;14(10):506-12 [7506035.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):922-6 [7883851.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1370-6 [7883984.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):147-57 [8551218.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):340-1 [8909643.001]
  • [Cites] FASEB J. 1996 Dec;10(14):1607-13 [9002552.001]
  • [Cites] Clin Biochem. 1997 Feb;30(1):53-6 [9056110.001]
  • [Cites] Infect Immun. 1997 Nov;65(11):4734-7 [9353058.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Biochimie. 1998 Aug-Sep;80(8-9):673-87 [9865490.001]
  • [Cites] J Urol. 1999 Aug;162(2):293-306 [10411025.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Oncology. 2004;67(5-6):359-67 [15713991.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):529-34 [15863156.001]
  • [Cites] J Thromb Haemost. 2008 Sep;6(9):1586-94 [18541003.001]
  • [Cites] Cancer Control. 2007 Oct;14(4):360-8 [17914336.001]
  • [Cites] Pathol Oncol Res. 2007;13(4):360-4 [18158573.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1508-17 [18257519.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1419-26 [18303830.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1395-402 [18303834.001]
  • [Cites] Cancer Biomark. 2008;4(2):73-81 [18503158.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):362-73 [19053527.001]
  • [Cites] Cancer Treat Rev. 2000 Apr;26(2):91-102 [10772967.001]
  • [Cites] Bioinformatics. 2005 May 15;21(10):2394-402 [15713736.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):345-51 [16410341.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):83-90 [16322896.001]
  • [Cites] Hell J Nucl Med. 2006 Jan-Apr;9(1):60-4 [16617400.001]
  • [Cites] BMC Bioinformatics. 2006;7:197 [16606446.001]
  • [Cites] IEEE Trans Med Imaging. 2006 May;25(5):571-81 [16689261.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):692-4 [16704450.001]
  • [Cites] Brain. 2006 Nov;129(Pt 11):3042-50 [17071923.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7 [17159154.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Proteomics. 2007 Jan;7(2):299-312 [17205601.001]
  • (PMID = 19476629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 84955; United States / NCI NIH HHS / CA / R01 CA-112437-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2696469
  •  go-up   go-down


78. Eyenga VC, Ngah JE, Atangana R, Etom E, Ngowe MN, Bassong Y, Oyono JL, Sosso M: [Central nervous system tumours in Cameroon: histopathology and demography]. Sante; 2008 Jan-Mar;18(1):39-42
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs du système nerveux central au Cameroun: histopathologie, démographie.
  • INCLUSION CRITERIA: All cases undergoing surgery in these units for a histologically-confirmed CNS tumour.
  • The average age of patients with metastatic tumors was 42+/-18.5 years compared with 36.5+/-17.8 years for cases with primary tumors.
  • Primary tumors were malignant in 34.2% (n=12) of the children and benign in 65.8% (n=23); among adults 22.7% (n=30) were malignant and 77.3% (n=102) benign.
  • In conclusion, CNS tumors occurred mainly before the age of 55 years and had a slight predilection for girls and women.
  • Meningiomas were the most frequent tumors in adults while astrocytomas were more prevalent in children.
  • [MeSH-major] Brain Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / epidemiology. Astrocytoma / pathology. Brain / pathology. Cameroon. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Meninges / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684690.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


79. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • Magnetic resonance imaging (MRI) revealed an extensive left temporal lobe tumor.
  • She underwent partial resection of the tumor under awake surgery, while preserving her language function.
  • The surgical specimen showed that the majority of the tumor was composed of a glioneuronal element.
  • Therefore, our first pathological diagnosis was oligoastrocytoma and DNT.
  • The tumor recurred at the left temporal lobe in June 2005.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • She received PAV (procarvazine, ACNU, and vincristine) chemotherapy, and the tumor subsided transiently.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


80. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • CONCLUSIONS: Bevacizumab seems to have a good acute safety profile and some antitumor activity in heavily pretreated children and young adults with recurrent solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


81. Sheridan T, Herawi M, Epstein JI, Illei PB: The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol; 2007 Sep;31(9):1351-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
  • It is expressed in both benign and neoplastic prostate tissues, but not in any other normal or malignant tissue examined to date.
  • The tissue microarray contains 78 cases of metastatic prostatic adenocarcinoma, 20 cases of primary prostatic adenocarcinoma, and 20 cases of benign prostate tissue from the peripheral zone as well as samples of benign brain, pancreas, kidney, thyroid, testis, skeletal muscle, and fibroconnective tissue.
  • RESULTS: Similar staining (intensity and extent) was identified for both markers in the majority of metastatic tumors (11 distant sites, 42 pelvic lymph nodes), in all 20 primary tumors and in all benign prostate and nonprostate tissues.
  • The P501S stain had perinuclear cytoplasmic (Golgi) distribution even in poorly differentiated tumors and metastases.
  • None of the tumors were negative for both markers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Membrane Proteins / analysis. Neoplasms, Unknown Primary / diagnosis. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Cell Differentiation. Golgi Apparatus / chemistry. Humans. Immunohistochemistry. Lymph Nodes / chemistry. Lymph Nodes / immunology. Male. Neoplasm Staging. Predictive Value of Tests. Reproducibility of Results. Sensitivity and Specificity. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721190.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / prostein; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


82. Shingu T, Akiyama Y, Daisu M, Maruyama N, Matsumoto Y, Miyazaki T, Nagai H, Yamamoto Y, Yamasaki T, Yoshida M, Maruyama R, Moritake K: Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):222-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and T(2)*-weighted magnetic resonance imaging revealed hemorrhage in the tumor located in the right basal ganglia, thalamus, and hypothalamus.
  • Although neither symptomatic hemorrhage nor late benign recurrence is common, careful long-term follow up is necessary for patients with pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Hemorrhage / etiology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527050.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Stevens QE, Howes G, Dickerman RD, Lee JM, Nardone EM: Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion? Clin Neurol Neurosurg; 2007 Feb;109(2):195-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For benign gangliogliomas, gross total resection can be curative; however, more aggressive variants may be resistant to multimodal therapies.
  • [MeSH-major] Brain Neoplasms / surgery. Ganglioglioma / surgery. Glioblastoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Multiple Primary / surgery. Temporal Lobe / surgery
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytes / pathology. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Dose Fractionation. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neuroglia / pathology. Neurologic Examination. Radiotherapy, Adjuvant. Reoperation

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056178.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


84. Zhou M, Xu G, Bojanowski CM, Song Y, Chen R, Sun X, Wang W, Chan CC: Differential diagnosis of anterior chamber cysts with ultrasound biomicroscopy: ciliary body medulloepithelioma. Acta Ophthalmol Scand; 2006 Feb;84(1):137-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of anterior chamber cysts with ultrasound biomicroscopy: ciliary body medulloepithelioma.
  • CONCLUSION: Intraocular medulloepithelioma is a rare embryonic benign or malignant neoplasm typically diagnosed in the first decade of life as a ciliary body mass.
  • Lack of glial differentiation may predict a better clinical outcome in primary neuroectodermal brain tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1999 Mar;83(3):334-8 [10365043.001]
  • [Cites] Ophthalmology. 1996 Dec;103(12):1998-2006 [9003333.001]
  • [Cites] Ann Neurol. 1996 Apr;39(4):481-9 [8619526.001]
  • [Cites] J Ultrasound Med. 2005 Feb;24(2):247-50 [15661960.001]
  • (PMID = 16445454.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Other-IDs] NLM/ NIHMS54981; NLM/ PMC2441603
  •  go-up   go-down


85. Plans G, Brell M, Cabiol J, Villà S, Torres A, Acebes JJ: Intracranial retrograde dissemination in filum terminale myxopapillary ependymomas. Acta Neurochir (Wien); 2006 Mar;148(3):343-6; discussion 346
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myxopapillary ependymomas (ME) are considered benign tumours (WHO grade I) of the central nervous system with long term survival rates and a tendency to local recurrence.
  • We describe the case of a 23-year-old man diagnosed with intracranial subarachnoid dissemination of a filum terminale ME three years after the initial diagnosis.
  • [MeSH-major] Brain Neoplasms / secondary. Cauda Equina / pathology. Ependymoma / secondary. Meningeal Neoplasms / secondary. Neoplasm Metastasis / physiopathology. Spinal Cord Neoplasms / pathology. Subarachnoid Space / physiopathology
  • [MeSH-minor] Adult. Decompression, Surgical. Disease Progression. Headache / diagnosis. Headache / etiology. Headache / physiopathology. Humans. Hypothalamic Neoplasms / radiotherapy. Hypothalamic Neoplasms / secondary. Hypothalamus / pathology. Hypothalamus / physiopathology. Hypothalamus / surgery. Laminectomy. Low Back Pain / etiology. Low Back Pain / physiopathology. Low Back Pain / surgery. Lumbar Vertebrae / surgery. Magnetic Resonance Imaging. Male. Pituitary Gland, Posterior / pathology. Pituitary Gland, Posterior / physiopathology. Pituitary Gland, Posterior / surgery. Radiotherapy / methods. Third Ventricle / pathology. Third Ventricle / physiopathology. Third Ventricle / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362177.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 35
  •  go-up   go-down


86. Amoli FA, Mehrabani PM, Tari AS: Aggressive orbital optic nerve meningioma with benign microscopic features: a case report. Orbit; 2007 Dec;26(4):271-4
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive orbital optic nerve meningioma with benign microscopic features: a case report.
  • Primary optic nerve meningiomas occur at lower ages than meningiomas arising from the coverings of the brain and spinal cord.
  • The patient had a history of orbital meningioma from 10 years ago and several surgical resections due to tumor recurrence during these 10 years.
  • Fine-needle aspiration cytology of the mass confirmed tumor recurrence.
  • The patient first received radiotherapy due to the inoperable mass, and the tumor was resected 1.5 month later.
  • The interesting aspect of this case was the aggressive behavior of the tumor with intraocular invasion, despite its benign histopathological features, which led to wide exenteration of the eye together with resection of the upper and lower lids.
  • [MeSH-major] Meningioma / pathology. Optic Nerve Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097966.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Pandita A, Balasubramaniam A, Perrin R, Shannon P, Guha A: Malignant and benign ganglioglioma: a pathological and molecular study. Neuro Oncol; 2007 Apr;9(2):124-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant and benign ganglioglioma: a pathological and molecular study.
  • Gangliogliomas are generally benign tumors, composed of transformed neuronal and glial elements, with rare malignant progression of the glial component.
  • Conventional and array comparative genomic hybridization (approximately 2.5-Mb resolution) analyses found chromosomal losses to be predominant in the benign areas of the ganglioglioma, with gains more prevalent in the malignant component.
  • Deciphering the specific genes residing in these chromosomal regions may further our understanding of not only these rare tumors but also the more common gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Ganglioglioma / genetics. Ganglioglioma / pathology
  • [MeSH-minor] Adult. Chromosome Mapping. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Genes, p16. Genes, p53. Humans. Oligonucleotide Array Sequence Analysis. Receptors, Androgen / genetics. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Genome Res. 2004;107(1-2):77-82 [15305059.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):262-75 [10935481.001]
  • [Cites] Neurosurgery. 1983 Aug;13(2):124-8 [6888690.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):501-8 [7856759.001]
  • [Cites] Am J Pathol. 1995 Mar;146(3):613-9 [7887443.001]
  • [Cites] Nucleic Acids Res. 1995 Apr 25;23(8):1411-8 [7753634.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5080-4 [7585555.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jul;55(7):822-31 [8965097.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):2034-9 [10471057.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):69-73 [15860361.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):103-6 [15925988.001]
  • [Cites] Adv Cancer Res. 2005;94:1-27 [16095998.001]
  • [Cites] Am J Dermatopathol. 2005 Aug;27(4):279-85 [16121045.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6177-85 [16144918.001]
  • [Cites] Lab Invest. 2001 May;81(5):717-23 [11351043.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):138-42 [11453385.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):807-12 [12213708.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):53-62 [12659670.001]
  • [Cites] Pathol Int. 2003 Dec;53(12):874-82 [14629754.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):667-74 [16465372.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R9 [16417655.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1571-83 [16247447.001]
  • [Cites] J Neurosurg. 1981 Jan;54(1):58-63 [7463121.001]
  • (PMID = 17259542.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC1871674
  •  go-up   go-down


88. Tamura K, Aoyagi M, Wakimoto H, Tamaki M, Yamamoto K, Yamamoto M, Ohno K: Malignant transformation eight years after removal of a benign epidermoid cyst: a case report. J Neurooncol; 2006 Aug;79(1):67-72
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation eight years after removal of a benign epidermoid cyst: a case report.
  • Malignant transformation of benign epidermoid cysts is rare and their prognosis remains poor.
  • She had undergone removal of a benign epidermoid cyst in the cerebellopontine angle 8 years previously.
  • Magnetic resonance imaging of the brain revealed a cystic lesion in the left cerebellopontine angle.
  • She underwent removal again and the histopathologic diagnosis was squamous cell carcinoma.
  • The tumor shrank rapidly for 2 months after radiosurgery, but recurred 9 months later.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Epidermal Cyst / pathology
  • [MeSH-minor] Female. Gadolinium. Humans. Image Enhancement. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):628-30 [7622698.001]
  • [Cites] No Shinkei Geka. 1987 Aug;15(8):851-8 [3323934.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1237-43 [12450053.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12(6):1182-4 [1763747.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):538-41 [6886769.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;402(4):459-64 [6202051.001]
  • [Cites] J Neurosurg. 1965 Oct;23(4):384-93 [5853888.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Jan;39(1):49-54 [10093462.001]
  • [Cites] Cancer. 1973 Mar;31(3):713-8 [4693599.001]
  • [Cites] Acta Neurochir (Wien). 1987;85(1-2):34-9 [3604769.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Jun;43(6):275-80; discussion 281 [12870545.001]
  • [Cites] J Clin Neurosci. 2001 Nov;8(6):572-4 [11683611.001]
  • [Cites] Cancer. 2005 May 15;103(10):2143-53 [15816051.001]
  • [Cites] J Neurosurg. 1979 Jun;50(6):830-3 [312314.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Mar-Apr;10(2):351-6 [2494855.001]
  • [Cites] J Neurosurg. 1964 Dec;21:1051-8 [14279825.001]
  • [Cites] Neurosurgery. 1989 Apr;24(4):574-8 [2651960.001]
  • [Cites] No Shinkei Geka. 1990 Nov;18(11):1041-5 [2247198.001]
  • [Cites] J Neurosurg. 1981 Oct;55(4):654-6 [7277016.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1965 Jun;28:276-81 [14345685.001]
  • [Cites] J Neurosurg. 1987 Apr;66(4):618-20 [3559730.001]
  • [Cites] Neurol Med Chir (Tokyo). 1989 Jul;29(7):600-5 [2477760.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):271-6 [299778.001]
  • [Cites] J Comput Assist Tomogr. 1981 Jun;5(3):433-5 [6972395.001]
  • [Cites] Br J Neurosurg. 1993;7(5):565-9 [8267896.001]
  • [Cites] Br J Neurosurg. 1991;5(3):303-5 [1892574.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):329-32 [7477788.001]
  • [Cites] No Shinkei Geka. 1995 Oct;23(10):905-9 [7477700.001]
  • [Cites] Curr Opin Oncol. 1997 May;9(3):262-6 [9229149.001]
  • (PMID = 16583265.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


89. Kuriakose MA, Trivedi NP, Kekatpure V: Anterior skull base surgery. Indian J Surg Oncol; 2010 Apr;1(2):133-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The basic principle of anterior skull base surgery is to provide adequate exposure to enable three dimensional resection of skull base tumors.
  • Negative surgical margins, which is within the control of surgeon, is the principle prognostic factor in anterior skull base tumors.
  • Open skull base approaches is the standard of care for malignant anterior skull base tumors.
  • Benign lesions may be resected by alternate minimally invasive approaches.
  • Advances in anterior skull base surgery, in particular the facial translocation approaches allows wide exposure of the tumors with minimal retraction of the brain.
  • The outcome of anterior skull base tumors have steadily increased over the years with disease free survival comparable to other malignant neoplasm of the head and neck region.
  • This review described various surgical approaches and pertaining anatomy and pathology of anterior skull base tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1979 Jul;89(7 Pt 1):1077-91 [449551.001]
  • [Cites] Arch Ophthalmol. 1977 Jul;95(7):1269-73 [880087.001]
  • [Cites] J Oral Maxillofac Surg. 1987 Jun;45(6):481-6 [3035154.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Head Neck. 2002 Mar;24(3):247-57 [11891956.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1871-6 [12368633.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1877-82 [12368634.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1897-901 [12368639.001]
  • [Cites] Head Neck. 2002 Oct;24(10):901-11; discussion 912 [12369068.001]
  • [Cites] Head Neck. 2003 Jul;25(7):515-20 [12808653.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Dec;119(12):1318-25 [17431985.001]
  • [Cites] Laryngoscope. 1988 Nov;98(11):1159-64 [3185068.001]
  • [Cites] Plast Reconstr Surg. 1985 Nov;76(5):695-702 [4059409.001]
  • [Cites] J Neurosurg. 1968 Apr;28(4):341-50 [5643926.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):489-97 [6486318.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Nov;121(11):1253-7 [7576471.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Nov;120(11):1203-8 [7917203.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):3-10 [8125786.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Jun;110(6):539-46 [8208569.001]
  • [Cites] J Craniofac Surg. 1993 Jul;4(3):142-7 [8241356.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):385-93 [8457302.001]
  • [Cites] Am J Otol. 1995 Jul;16(4):465-9 [8588646.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Sep;17(8):1569-74 [8883658.001]
  • [Cites] Plast Reconstr Surg. 1996 Dec;98(7):1159-66; discussion 1167-8 [8942901.001]
  • [Cites] Br J Plast Surg. 1996 Dec;49(8):519-28 [8976743.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Mar;123(3):290-6 [9076235.001]
  • [Cites] Head Neck. 1997 Aug;19(5):391-9 [9243266.001]
  • [Cites] Am J Otolaryngol. 1997 Nov-Dec;18(6):431-3 [9395024.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Dec;123(12):1312-7 [9413360.001]
  • [Cites] Head Neck. 1998 May;20(3):193-6 [9570623.001]
  • [Cites] Head Neck. 1999 Jan;21(1):12-20 [9890346.001]
  • [Cites] Head Neck. 1999 Aug;21(5):402-7 [10402519.001]
  • [Cites] Am J Rhinol. 1999 Jul-Aug;13(4):303-10 [10485018.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):541-9 [10701732.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):396-401 [10722015.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):711-4 [11014555.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1296-304; discussion 1304-5 [11126900.001]
  • [Cites] Neurosurgery. 2001 Jan;48(1):232-3; discussion 233-4 [11152355.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):483-7 [11224780.001]
  • [Cites] Plast Reconstr Surg. 2001 May;107(6):1346-55; discussion 1356-7 [11335798.001]
  • [Cites] Arch Facial Plast Surg. 2001 Apr-Jun;3(2):79-90 [11368657.001]
  • [Cites] Laryngoscope. 2001 Jul;111(7):1306-12 [11568560.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Br J Radiol. 2002 Apr;75(892):345-50 [12000693.001]
  • [Cites] Laryngoscope. 2002 Mar;112(3):424-7 [12148847.001]
  • [Cites] Plast Reconstr Surg. 2002 Oct;110(5):1303-9 [12360072.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Oct;128(10):1196-7 [12365893.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):568-74; discussion 575 [12560677.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Plast Reconstr Surg. 2003 Aug;112(2):703-4 [12900649.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Cancer. 1954 Sep;7(5):991-4 [13199776.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):53-6; discussion 56-7 [14740265.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):167-86 [15062368.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):528-32 [15091229.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):1-8 [15100925.001]
  • [Cites] Acta Otorrinolaringol Esp. 2004 Jan;55(1):27-33 [15108619.001]
  • [Cites] Am J Otolaryngol. 2004 May-Jun;25(3):162-6 [15124164.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Jun;130(6):780-7 [15195067.001]
  • [Cites] J Otolaryngol. 2004 Feb;33(1):32-6 [15291274.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):107-31, ix [15649503.001]
  • [Cites] Head Neck. 2005 Jun;27(6):445-51 [15825205.001]
  • [Cites] J Craniofac Surg. 2005 Nov;16(6):1085-91 [16327559.001]
  • (PMID = 22930628.001).
  • [ISSN] 0975-7651
  • [Journal-full-title] Indian journal of surgical oncology
  • [ISO-abbreviation] Indian J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3421004
  • [Keywords] NOTNLM ; Anterior skull base surgery / Craniofacial resection / Skull base reconstruction / Skull base surgery
  •  go-up   go-down


90. Charpiot A, Tringali S, Zaouche S, Ferber-Viart C, Dubreuil C: Perioperative complications after translabyrinthine removal of large or giant vestibular schwannoma: Outcomes for 123 patients. Acta Otolaryngol; 2010 Nov;130(11):1249-55
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Large vestibular schwannomas are benign but dangerous tumors.
  • [MeSH-minor] Adult. Aged. Aphasia / etiology. Brain Stem / pathology. Cerebrospinal Fluid Leak. Cerebrospinal Fluid Rhinorrhea / etiology. Edema / etiology. Electromyography. Epilepsy / etiology. Facial Nerve / physiopathology. Female. Follow-Up Studies. Hematoma, Subdural / etiology. Hematoma, Subdural / surgery. Humans. Magnetic Resonance Imaging. Male. Meningitis / etiology. Middle Aged. Neoplasm Staging. Nervous System Diseases / etiology. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Otolaryngol. 2011 Nov;131(11):1237-8 [21728749.001]
  • (PMID = 20443757.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Shen R, Pan S, Qi S, Lin X, Cheng S: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun; 2010 Apr 16;394(4):1047-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High levels of SOX4 expression have been found in a variety of human cancers, such as lung, brain and breast cancers.
  • The SOX4 expression was detected using immunohistochemical staining and semi-quantitative RT-PCR, and our results showed that SOX4 was up-regulated in gastric cancer compared to benign gastric tissues.
  • [MeSH-major] Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. MicroRNAs / metabolism. SOXC Transcription Factors / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Apoptosis / genetics. DNA Methylation. Down-Regulation. Gene Expression Profiling. Humans. Neoplasm Metastasis. Prognosis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20331975.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Mirn129 microRNA, human; 0 / SOX4 protein, human; 0 / SOXC Transcription Factors
  •  go-up   go-down


92. McGregor JM, Sarkar A: Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas. Otolaryngol Clin North Am; 2009 Aug;42(4):677-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common nonglial brain tumors.
  • They tend to be slow growing and benign and can reach substantial sizes before becoming symptomatic.
  • Location of a meningioma within the cranial vault may make complete surgical resection unlikely; tumors arising from the dura of the skull base are particularly challenging.
  • They may be used as adjuncts to surgery or as alternative modalities in the treatment of these complex tumors.
  • [MeSH-major] Meningioma / radiotherapy. Meningioma / surgery. Neoplasm Recurrence, Local / pathology. Radiosurgery / methods. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Cranial Irradiation / adverse effects. Cranial Irradiation / methods. Dose-Response Relationship, Radiation. Female. Humans. Immunohistochemistry. Male. Meningeal Neoplasms / mortality. Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Radiation Injuries / prevention & control. Radiotherapy Dosage. Risk Assessment. Stereotaxic Techniques. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751872.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


93. Skube SB, Chaverri JM, Goodson HV: Effect of GFP tags on the localization of EB1 and EB1 fragments in vivo. Cytoskeleton (Hoboken); 2010 Jan;67(1):1-12
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that neither N-terminal nor C-terminal tags are benign: tagged EB1 and EB1 fragments generally behave differently from their untagged counterparts.
  • C-terminally tagged EB1 constructs have localizations similar to the untagged constructs, initially suggesting that they are benign.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 2007 Feb;64(3):307-17 [17221167.001]
  • [Cites] Cell. 2006 Dec 29;127(7):1415-24 [17190604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10346-51 [17563362.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):976-91 [17889670.001]
  • [Cites] Nat Struct Mol Biol. 2007 Oct;14(10):959-67 [17828277.001]
  • [Cites] Eukaryot Cell. 2007 Dec;6(12):2354-64 [17766466.001]
  • [Cites] Biochemistry. 2008 Jan 15;47(2):779-86 [18081319.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Apr;9(4):309-22 [18322465.001]
  • [Cites] J Cell Sci. 2008 Jul 15;121(Pt 14):2372-81 [18577573.001]
  • [Cites] J Cell Biol. 2008 Dec 29;183(7):1223-33 [19103809.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):492-7 [19126680.001]
  • [Cites] J Cell Biol. 2009 Mar 9;184(5):691-706 [19255245.001]
  • [Cites] Cold Spring Harb Protoc. 2010 Sep;2010(9):pdb.top85 [20810643.001]
  • [Cites] Mol Biol Cell. 1999 Dec;10(12):4107-20 [10588646.001]
  • [Cites] Oncogene. 2000 Apr 6;19(15):1950-8 [10773885.001]
  • [Cites] Curr Biol. 2000 Jul 13;10(14):865-8 [10899006.001]
  • [Cites] Cell. 2001 May 18;105(4):421-4 [11371339.001]
  • [Cites] Oncogene. 2001 May 31;20(25):3185-92 [11423968.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Jan 31;98(1-2):145-52 [11834307.001]
  • [Cites] Mol Biol Cell. 2002 Oct;13(10):3627-45 [12388762.001]
  • [Cites] Mol Biol Cell. 2003 Mar;14(3):916-25 [12631713.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):2655-64 [12684451.001]
  • [Cites] Mol Biol Cell. 2003 Apr;14(4):1405-17 [12686597.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):753-8 [12700769.001]
  • [Cites] Trends Cell Biol. 2003 May;13(5):229-37 [12742166.001]
  • [Cites] Cell Motil Cytoskeleton. 2003 Jul;55(3):156-73 [12789661.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):812-8 [12894167.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36430-4 [12857735.001]
  • [Cites] Cell. 2003 Oct 31;115(3):343-54 [14636561.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49721-31 [14514668.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1584-8 [14747658.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1776-84 [14767058.001]
  • [Cites] Curr Biol. 2004 Apr 20;14(8):725-30 [15084289.001]
  • [Cites] Nat Cell Biol. 2004 Sep;6(9):820-30 [15311282.001]
  • [Cites] J Biol Chem. 1991 Sep 15;266(26):17597-605 [1680130.001]
  • [Cites] Cell. 1992 Sep 18;70(6):887-900 [1356075.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2972-7 [7606712.001]
  • [Cites] Mol Biol Cell. 1997 Dec;8(12):2677-91 [9398684.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:83-117 [9442869.001]
  • [Cites] J Cell Biol. 1998 May 18;141(4):849-62 [9585405.001]
  • [Cites] Oncogene. 1998 Dec 31;17(26):3471-7 [10030671.001]
  • [Cites] Curr Biol. 1999 Apr 22;9(8):425-8 [10226031.001]
  • [Cites] J Cell Biol. 1999 May 31;145(5):993-1007 [10352017.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):141-53 [15631994.001]
  • [Cites] Curr Opin Cell Biol. 2005 Feb;17(1):47-54 [15661518.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):261-9 [15616574.001]
  • [Cites] J Cell Biol. 2005 Feb 14;168(4):587-98 [15699215.001]
  • [Cites] Mol Cell. 2005 Aug 19;19(4):449-60 [16109370.001]
  • [Cites] J Cell Sci. 2005 Sep 15;118(Pt 18):4113-22 [16118246.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):197-200 [16247021.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):201-7 [16247022.001]
  • [Cites] Mol Biol Cell. 2005 Nov;16(11):5334-45 [16148041.001]
  • [Cites] FEBS Lett. 2006 Feb 20;580(5):1327-32 [16455083.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1483-93 [16407408.001]
  • [Cites] Traffic. 2006 May;7(5):499-507 [16643273.001]
  • [Cites] J Cell Sci. 2006 Aug 1;119(Pt 15):3193-205 [16868032.001]
  • [Cites] Mol Cell. 2006 Sep 1;23(5):663-71 [16949363.001]
  • [Cites] Mol Biol Cell. 2006 Oct;17(10):4420-34 [16899509.001]
  • [Cites] J Mol Biol. 2007 Apr 27;368(2):550-63 [17350042.001]
  • (PMID = 19701929.001).
  • [ISSN] 1949-3592
  • [Journal-full-title] Cytoskeleton (Hoboken, N.J.)
  • [ISO-abbreviation] Cytoskeleton (Hoboken)
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM065420-05; United States / NIGMS NIH HHS / GM / R01 GM065420; United States / NIGMS NIH HHS / GM / R01 GM065420-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MAPRE1 protein, human; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; 148349-95-5 / cytoplasmic linker protein 170
  • [Other-IDs] NLM/ NIHMS149897; NLM/ PMC2909448
  •  go-up   go-down


94. Gole B, Durán Alonso MB, Dolenc V, Lah T: Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol Oncol Res; 2009 Dec;15(4):711-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cells that migrate away from a central tumour into brain tissue are responsible for inefficient glioblastoma treatment.
  • Reportedly, the expression of cathepsins B, L and S gradually increases in the progression from benign astrocytoma to the malignant glioblastoma, although their specific roles in glioma progression have not been revealed.
  • However, using specific synthetic inhibitors and silencing strategies revealed that only cathepsin B activity was involved in the invasion of glioblastoma cells, confirming previous notion of cathepsin B as tumour invasiveness biomarker.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cathepsin B / metabolism. Cell Movement / physiology. Glioblastoma / metabolism. Glioblastoma / pathology. Protein Biosynthesis / physiology
  • [MeSH-minor] Adult. Aged. Cathepsin L / metabolism. Cathepsins / metabolism. Cell Line, Tumor. Collagen / metabolism. Cystatins / metabolism. Drug Combinations. Female. Humans. Laminin / metabolism. Male. Middle Aged. Neoplasm Invasiveness / physiopathology. Proteoglycans / metabolism. Spheroids, Cellular / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8705-12 [12483523.001]
  • [Cites] Exp Cell Res. 2003 Feb 15;283(2):206-14 [12581740.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):825-38 [14505115.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):775-9 [11857353.001]
  • [Cites] Methods Enzymol. 1994;244:685-700 [7845245.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):175-82 [12819022.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):315-20 [15781318.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):207-23 [15799821.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):1008-15 [16153465.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3357-64 [17094453.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):27-34 [8521613.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):819-24 [14505114.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2735-43 [16381007.001]
  • [Cites] Cancer Gene Ther. 2003 Feb;10(2):141-51 [12536203.001]
  • [Cites] Biol Chem. 2003 Mar;384(3):447-55 [12715895.001]
  • [Cites] Acta Neuropathol. 1997 May;93(5):494-500 [9144588.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104 [16831080.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10 ):800-8 [17851543.001]
  • [Cites] Clin Exp Metastasis. 1994 Nov;12(6):405-15 [7923993.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2064-9 [10815933.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):854-60 [16550604.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9147-56 [19010886.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] BMC Genomics. 2008 Jan 29;9:54 [18230158.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):543-56 [16481467.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):161-76 [11716068.001]
  • [Cites] Expert Opin Biol Ther. 2006 Mar;6(3):257-79 [16503735.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] Biophys J. 2008 Dec 15;95(12):5661-80 [18835895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7883-8 [12048238.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):297-309 [17928955.001]
  • [Cites] Biophys J. 2006 Oct 1;91(7):2708-16 [16829558.001]
  • [Cites] Biol Chem. 2001 May;382(5):785-8 [11517931.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):559-67 [10100707.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3197-208 [17172424.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):90-3 [10763148.001]
  • [Cites] Cancer Detect Prev. 2005;29(5):448-55 [16183211.001]
  • (PMID = 19434518.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cystatins; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.- / Cathepsins; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / Cathepsin L; EC 3.4.22.27 / cathepsin S
  •  go-up   go-down


95. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One; 2009;4(4):e5052
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent advances in diagnosis and treatment, the mortality rates with an overall 5-year survival of only 15%.
  • METHODOLOGY/PRINCIPAL FINDINGS: To identify novel lung adenocarcinoma-associated /metastasis genes and to clarify the underlying molecular mechanisms of these targets in lung cancer progression, we created a bioinformatics scheme consisting of integrating three gene expression profile datasets, including pairwise lung adenocarcinoma, secondary metastatic tumors vs. benign tumors, and a series of invasive cell lines.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Cycle Proteins / physiology. Lung Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Nuclear Proteins / physiology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Up-Regulation / physiology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Enzyme Activation. Gene Knockdown Techniques. Humans. Microscopy, Fluorescence. RNA, Messenger / genetics. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):483-7 [10591207.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):660-4 [12869408.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7 [14641020.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):294-300 [14656735.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):510-8 [15093181.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32592-602 [15145941.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):667-76 [15505410.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):64-8 [9036871.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Br J Cancer. 1997;76(8):1041-5 [9376264.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5223-30 [11431363.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1953-62 [11532975.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400 [11562390.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):558-63 [11870537.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32521-7 [9405464.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1483-7 [9626466.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10002-7 [10187776.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Lung. 2004;182(3):151-62 [15526754.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):477-88 [16198290.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):830-8 [16256070.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7443-54 [16288291.001]
  • [Cites] Mol Cell. 2005 Nov 23;20(4):539-50 [16307918.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):306-14 [16330671.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):480-6 [16170351.001]
  • [Cites] Genomics. 2006 Feb;87(2):243-53 [16406728.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):53-9 [15899546.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23285-95 [16787925.001]
  • [Cites] Mol Biol Cell. 2006 Sep;17(9):3881-96 [16790497.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Feb;8(2):140-9 [17328230.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):7758-69 [17178724.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4272-83 [17237822.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82 [17540577.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Behav Brain Res. 2002 Nov 15;136(2):489-501 [12429412.001]
  • (PMID = 19337377.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cep55 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2659802
  •  go-up   go-down


96. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


97. Kars M, Roelfsema F, Romijn JA, Pereira AM: Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol; 2006 Oct;155(4):523-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In general, the initial clinical, biochemical, and histological characteristics are of minimal utility in distinguishing benign adenomas from pituitary carcinomas.
  • In brief, it is postulated that pituitary carcinomas arise from the transformation of initially large, but benign, adenomas.
  • In vivo, the development of dopamine agonist resistance in invasive macroprolactinoma is indicative of malignancy and should prompt the clinician to perform a biopsy of the tumor.
  • For pituitary tumors that exhibit high mitotic activity, increased Ki-67 and/or p53 immunoreactivity, it may be useful to denote these tumors as 'atypical' prolactinomas to raise the possibility of future malignant development.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990651.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Pyrrolidines; 107188-87-4 / epidepride; 9002-62-4 / Prolactin
  • [Number-of-references] 47
  •  go-up   go-down


98. Aguirre-Quezada DE, Martínez-Anda JJ, Aguilar-Ayala EL, Chávez-Macías L, Olvera-Rabiela JE: [Intracranial and intramedullary peripheral nerve sheath tumours. Case reports from 20 autopsies]. Rev Neurol; 2006 Aug 16-31;43(4):197-200
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumores de vaina de nervio periférico intracraneales e intrarraquídeos. Informe de 20 casos de autopsia.
  • INTRODUCTION: Tumors arising from the sheath of peripheral nerves, both intracranial and intraspinal, are uncommon and are sometimes of difficult clinical diagnosis, especially when they occur in unusual sites.
  • Histological malignancy of this neoplasm is rare.
  • MATERIALS AND METHODS: The clinical and pathological findings of 20 autopsy cases of intracranial and intraspinal peripheral nerve tumors are analyzed.
  • 14 cases were surgically treated and the causes of death were ischemic lesions due to the large size of the tumors.
  • The correct clinical diagnosis was made in 14 patients.
  • The importance of early detection on intracranial and intraspinal peripheral tumors is paramount, since the large size of these histologically benign neoplasms makes them biologically malignant.
  • [MeSH-major] Brain Neoplasms / pathology. Cranial Nerve Neoplasms / pathology. Nerve Sheath Neoplasms / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Autopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neurilemmoma / pathology. Neurofibromatosis 1 / pathology. Neurofibromatosis 2 / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883507.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Cheong JH, Kim JM, Bak KH, Kim CH, Oh YH, Park DW: Bilateral vidian nerve schwannomas associated with facial palsy. Case report and review of the literature. J Neurosurg; 2006 May;104(5):835-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial schwannomas are relatively common benign tumors arising from Schwann cells.
  • [MeSH-major] Bell Palsy / etiology. Brain Neoplasms / surgery. Cranial Nerve Neoplasms / surgery. Facial Nerve Diseases / surgery. Neoplasms, Multiple Primary / surgery. Neurilemmoma / surgery
  • [MeSH-minor] Adolescent. Facial Nerve / pathology. Facial Nerve / surgery. Female. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis. Postoperative Complications / diagnosis. Sphenoid Bone / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2007 Jan;106(1):202; author reply 202-3 [17236512.001]
  • (PMID = 16703893.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg; 2005 Jan;102(1 Suppl):59-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.
  • Myxopapillary ependymomas (MPEs) have historically been thought to be benign tumors occurring most frequently in adults.
  • Only 8 to 20% of these tumors occur in the first two decades of life, making this tumor a rarity in pediatric neurosurgery.
  • In those cases in which patients underwent screening for CNS tumor dissemination, however, the incidence of disseminated disease was 58% (seven of 12 patients).
  • In pediatric patients MPEs may spread throughout the CNS via cerebrospinal fluid pathways; therefore, MR imaging of the entire CNS axis is recommended at both presentation and follow-up review to detect tumor dissemination.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Ependymoma / secondary. Neoplasm Metastasis. Spinal Cord Neoplasms / pathology






Advertisement